Prescribing habits in the pharmacotherapy of schizophrenia by King, Russell Wayne
 7709315   i
 
Prescribing habits in the pharmacotherapy of 
schizophrenia 
 
by 
 
Russell Wayne King 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This research report is submitted to the University  
of the Witwatersrand in partial fulfilment of  
the requirements for the degree of Master of  
Science (Med) in Pharmaceutical Affairs in 2011 
 7709315   ii
 
Dedication 
 
 
To Mia
 7709315   iii 
 
Acknowledgements 
 
I would like to thank Professor Paul Danckwerts for his support and 
assistance in supervising the research and write-up of this report 
 7709315   iv
Declaration  
 
I hereby certify that the research and write-up of this report  
were undertaken by me with the assistance of Professor  
Paul Danckwerts.  No other parties were involved 
 
 
Signed 
 
 
R W King 
 7709315   v
Abstract 
 
Background:  Many factors affect the prescribing of medication to patients with 
schizophrenia including variables that relate to physicians and may result in marked 
variance in the choice of drugs, dosages, drug combinations, route of administration and 
the use of antipsychotic, anticholinergic, sedative and other adjuvant drugs. 
 
Clinical practice guidelines were developed to address this variance and for other reasons, 
including the management of side-effects, drug innovation, rising costs, information 
overload, changes in treatment goals and the management of medication non-adherence.  
There are advantages and disadvantages to using clinical practice guidelines including 
those pertaining to context and cultural norms, but they remain the best method of 
assessing prescribing quality.   
 
Many guidelines are based on the results of randomised clinical trials (with a single drug) 
or are the consensus of experts in the field.  Despite the development and publication of 
these guidelines over the past two decades, they are frequently not adhered to resulting in 
much variance in treatment.   
 
Aims and objectives:  The aim of the study was to determine to what extent the 
prescribing of psychotropic drugs in the treatment of schizophrenia was consistent with the 
most recent version of each of five guidelines that originate outside South Africa (two from 
the United States and one each from Canada, the United Kingdom, and Australia and New 
Zealand); and one that was developed locally.   
 
Methodology:  A retrospective, cross-sectional prescription chart review with data 
sampling at three time points (on hospital admission, at fourteen days thereafter and on 
hospital discharge) was undertaken.  A sample population was drawn over a three year 
period during which the patients’ physician had access to the same drug formulary.  
Seventy patients met the study selection criteria in terms of age, diagnosis and receipt of 
antipsychotic medication during hospital stay and on discharge.  Seventy patients met the 
study selection criteria, and their prescriptions for psychotropic medication (exclusively) 
were examined for a number of parameters including:  drug class, drug name, dose, route 
of administration and whether the medication was to be administered routinely or ‘as 
needed’.   
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Findings and discussion:  As compared with the recommendations made in some or all 
of the guidelines, first generation antipsychotic agents were over-prescribed especially 
early on in the patients’ hospital stay, whereas second generation antipsychotics were 
under-prescribed.  The profile changed after fourteen days and on discharge there were 
more patients on second generation drugs than on the older drugs.  More patients were 
discharged on depot antipsychotic treatment than were admitted which is considered a 
favourable finding, however, many patients receiving the depot form continued to be 
prescribed the oral drug on a routine basis and for an indefinite period, resulting in 
antipsychotic polypharmacy. 
 
Anticholinergic drugs were prescribed as prophylaxis for the extra-pyramidal side-effects 
of the first generation antipsychotic drugs and more than a quarter of the sample received 
these drugs on discharge, after which they were to be taken routinely and indefinitely.   
 
A similar finding was made with the use of benzodiazepine sedatives, where nearly a 
quarter of patients received these drugs on discharge - again to be taken routinely and for 
an unspecified period. 
 
Sodium valproate was given increasingly to many patients in the sample and was 
prescribed to over a quarter of those upon discharge, without an indication of duration.   
 
Limitations:  The study was retrospective in design, without the benefit of the patients’ 
clinical histories and treatment progress, and the findings were compared with guidelines 
whose age spanned more than a decade and some of which had become redundant.   
 
Conclusions:  The study demonstrated some prescribing habits that were not in accord 
with the guidelines used for comparison in the study.  The extent of the disagreement 
reveals the need for a prospective pilot study that will include the patients’ clinical progress 
in the study design which will provide greater insight into why specific medication 
parameters were chosen by the physician for the individual patient.  If the findings justify it, 
then a programme promoting better adherence to the most current guidelines should be 
commenced.   
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Chapter 1 – Introduction 
 
1.1.  Preamble, aims and objectives 
 
1.1.1. Preamble 
 
The most common intervention performed by physicians is the writing of a prescription 
(Onalaja et al, 2001), however, all elements in the complex process of prescribing and 
administering drugs are susceptible to many variables including the relative availability of 
drugs (Bowers et al, 2004) and those related to physicians (Hamann et al, 2004) including 
medication errors (Ferner, 1995).   
 
Guidance on psychotropic prescribing exists in many forms, the manufacturer’s summary 
of product characteristics is the most important , however, there are numerous clinical 
practice guidelines to assist physicians prescribing for schizophrenia including the 
document ‘Guidance on the use of newer antipsychotic drugs for the treatment of 
schizophrenia (NICE, 2004).  However, in clinical practice, psychiatrists’ prescribing 
patters are often divergent (Hodgson & Belgamwar, 2006) and deviate from recommended 
practice (Paton et al, 2003).  This is evident in many ways including (inter alia): 
 
- The use of medications on an as required (pro re nata or ‘PRN’) basis on psychiatric 
inpatient wards being common and widespread but without clear evidence of effectiveness 
and may be associated with a greater risk of adverse events (Srivastava, 2009) including 
cytochrome P450 mediated interactions (Davies et al, 2007).   
 
- Prescriptions are often seen for more than one antipsychotic drug despite there being no 
efficacy advantage (Harrington et al, 2002), the practice not being based on scientific 
evidence (Taylor, 2010) and may result in a need for anticholinergic medication to combat 
the side-effects that occur as a consequence thereof  (Paton et al, 2003).   
 
- High dose antipsychotic prescribing is also common in clinical practice (Paton et al, 
2008) 
 
- Long-acting injections of antipsychotic medication were developed specifically to promote 
treatment adherence.  Approximately 40 to 60% of patients with the diagnosis of 
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schizophrenia are partially or totally non-compliant, yet only 30% or less are prescribed 
medication in this form.  (Patel et al, 2009) 
 
Despite these prescribing practices, there is a lack of routine data collection regarding 
acute ward prescribing (Paton & Lelliott, 2004).  This is unfortunate because audit is a 
valuable tool for monitoring compliance to prescribing and administration standards, for 
encouraging continued improvement in practice (Onalaja et al, 2001) and improving 
prescription writing (Shaughnessy & D’Amico, 1994).  
 
 
1.1.2. Aim of the study 
 
The study was conducted at a large state psychiatric hospital in South Africa with an 
annual average admission and discharge rate of over a thousand patients.  The hospital is 
divided into two groups of wards – for forensic and non-forensic patients – prescriptions 
from only the non-forensic patient were used re used in the study, the aim of which was to 
determine to what extent the prescribing of psychotropic drugs at the Facility corresponds 
with six clinical practice guidelines - five that originate outside South Africa and one that 
was developed locally - for the pharmacological treatment of schizophrenia.  
 
 
1.1.3. Objectives 
 
The objectives of the study are twofold.  Firstly, to obtain the appropriate data from the 
prescriptions of selected patients, to analyse it and to compare the results with the 
recommendations made in the guidelines; and secondly, to determine what course of 
action may be taken should the comparison reveal prescribing that deviates markedly or is 
idiosyncratic – for example the results may prompt prospective study to quantify and 
qualify the degree of deviation from the guidelines consulted in the study. 
 
 
1.2. Clinical practice guidelines 
Clinical practice guidelines may be defined as ‘systematically developed statements to 
assist practitioners and patient make decisions about appropriate care for specific 
circumstances’ (Field & Lohr, 1990). In recent years we have witnessed the dissemination 
of practice guidelines for the treatment of schizophrenia (Essock, 2002). Although these 
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guidelines are not a substitute for clinical judgement, professionals are expected to take 
them fully into account when exercising their clinical judgement (National Institute for 
Clinical Excellence, 2002), however, in a complex condition such as schizophrenia, it is 
neither possible nor sensible to be rigid (Rowlands, 2004).    
 
 
1.3.  Drivers for clinical practice guideline development 
The broad interest in clinical practice guidelines has its origin in issues that most 
healthcare systems face: the availability of new medicines (Dassori et al, 2000); the 
management of key adverse events (Briggs et al, 2008); rising costs; changes in treatment 
goals (Chue, 2006); variations in service delivery among providers, hospitals and 
geographic regions; and the intrinsic desire of healthcare professionals to offer the best 
care possible (Woolf et al, 1999).  Furthermore, a number of important questions 
concerning medication selection, dosing and the management of inadequate response 
have prompted guideline development and use (Kane et al, 2003). 
 
 
1.2.1  Drug innovation and the management of side-effects 
 
First generation antipsychotics (FGAs) have been used to treat psychosis since 
chlorpromazine was introduced in the 1950s (Dunlop et al, 2003).  FGAs are highly 
effective; their therapeutic mechanism of action is thought to be closely related to the 
blockade of dopamine receptors which is also the reason for their side-effects including 
elevated prolactin levels (Volavka & Citrome, 2009) and movement disorders such as 
Parkinsonism, akathisia, dystonia and tardive dyskinesia (Thompson, 1994; Sernyak et al, 
2002).  All FGAs share these properties (Thompson, 1994). 
 
The pharmacological treatment of schizophrenia has changed dramatically in recent years 
with the development of second generation antipsychotics (SGAs) (Chakos et al, 2001), 
the mechanism of action of which is serotonin-dopamine antagonism (Kaplan & Sadock, 
2006).  Although the SGAs have an improved side-effect profile, there is little to guide 
clinicians in choosing among them (McCue et al, 2006).   
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1.2.2  Rising costs 
 
In the early 1990s it was predicted that practice guidelines would improve the cost-
effectiveness of care (Field & Lohr, 1990).  It has been found that when clinicians use 
clinical practice guidelines organisations, resources are utilised more efficiently 
(Bahtsevani et al, 2004) and costs are reduced (Goel & Trivedi, 2007).   
 
Examination of antipsychotic medication use patterns has suggested that current 
prescribing practices do not mirror recommended treatment guidelines and this may have 
adverse economic consequences (Loosbrock et al, 2003).  An example of this is 
antipsychotic polypharmacy – it is inconsistent with current treatment guidelines and has 
been shown to be costly (Eisen et al, 2008). 
 
Numerous studies suggest that despite being more expensive than FGAs, SGAs are more 
cost-effective (Gianfrancesco et al, 2002; Hosak & Bahbouh, 2002; Palmer et al, 2002; 
Tilden et al, 2002).  More recent studies have found the opposite (Davies et al, 2007; 
Rosenheck et al, 2006) and Leucht et al (2008) have determined that SGA drugs differ in 
many properties and are not a homogeneous class, making it necessary for the clinician to 
make an individualised treatment choice based on efficacy, side-effects and cost.  This is 
also the view expressed in the clinical practice guidelines issued by the National Institute 
for Clinical Excellence (2009) and the American Psychiatric Association (2004).  This 
remains a controversial issue. 
 
 
1.2.3  Variance in service delivery and the potential for harm 
 
Health care delivered in ignorance of available research evidence, misses important 
opportunities to benefit patients and may cause significant harm (Dopson et al, 1994; 
Venturini et al, 1999).   
 
 
1.2.4   Information overload and the provision of the best care 
 
Practising clinicians are faced with large amounts of information to absorb in order to be 
able to advise their patients about the appropriate choice of medication (Bebbington, 
2001).  In an era of information overload, guidelines to best clinical practice are crucial for 
patients (Bolster, 1999). 
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1.2.5  Changes in treatment goals and the management of antipsychotic non-
adherence 
 
The goals of treatment in schizophrenia have evolved from objective improvements in 
psychotic symptoms to include patient-related factors such as subjective response and 
quality of life (Chue. 2006).  Relapse has the highest impact on quality of life and stable 
schizophrenia the lowest and so keeping the patient well is the utmost priority (Briggs et al, 
2008).   
 Patient satisfaction with antipsychotic therapy is influenced by multiple factors including 
inter alia: lack of involvement in treatment planning or decision making (Chue, 2006), a 
complicated treatment regimen (Burton, 2005), lack of efficacy (Mojtabai et al, 2009) and – 
most authors agree - drug side-effects (Briggs et al, 2008; Chue, 2006; Mojtabai et al, 
2009).  However, McCann et al (2009) found the relationship between treatment 
nonadherence and drug side-effects to be unclear.   
 
Nonadherence to antipsychotic medication has received increasing attention since the 
1980s (Marder, 1986) and remains a common and significant problem affecting the 
continuity of treatment in routine care settings (Charpentier et al, 2009; McCann et al, 
2009; Mojtabai et al, 2002; Valenstein et al, 2004; Valenstein et al, 2006, Zygmunt et al, 
2002).  Figures of non-adherence vary between a third (West et al, 2005) and as much as 
a half (Hudson et al, 2004; Lacro et al, 2002).   
 
The majority of studies have demonstrated that SGAs are associated with significant 
improvements in quality of life, functional status and patient satisfaction compared with 
FGAs (Chue, 2006).  Dolder et al (2002) compared FGA and SGA adherence in 
outpatients and found that compliance rates at 6 and 12 months were higher in patients 
who received the newer drugs.  However, in a study be Kilian et al (2004) SGAs caused 
no better quality of life than FGAs.  What is clear is that despite the introduction of these 
drugs, a leading cause of suboptimal outcome remains poor patient adherence to oral 
medication (Burton, 2005).  
 
 
1.4.  Implementation of clinical practice guidelines 
Distribution of guidelines is not the same as implementation (Bero et al, 1998; Clark, 
2003).  Our knowledge of scientific treatment practices does not always translate into 
better care and outcomes for patients (Drake et al, 2009; Fischer et al, 2008; McCarthy et 
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al, 2007; Mojtabai et al, 2009; Moran et al, 2006; Valenstein et al, 2004; Valenstein et al, 
2006;) and prescribing in everyday practice frequently deviates from guidelines 
(Harrington et al, 2002; Lelliott et al, 2002; Mamdani et al, 2008).  
 
While the potential of clinical practice guidelines to support implementation of guidelines 
has been demonstrated, it is not currently being achieved (Grimshaw et al, 2004).  There 
may be many reasons for this including inter alia: institutional barriers (Cabana et al, 1999; 
Francke, et al, 2008) for example, interventions that have strong evidence of efficacy may 
not be available in routine practice (Singh et al, 2003); patient characteristics including co-
morbidity (Francke et al, 2008), receiving depot antipsychotics (Meagher & Moran, 2003) 
and being an outpatient (Dickey et al, 2003; Mojtabai et al, 2009); and physician 
characteristics such as a lack of support from peers or superiors, as well as insufficient 
staff and time (Francke et al, 2008) and deficiencies in knowledge (Rowlands, 2004).  
Young et al (2006) found that psychiatrists who demonstrated greater adherence to 
guidelines were male, in midcareer, a caseload with a large proportion of patients with 
schizophrenia and use of current information from scientific literature or from 
pharmaceutical company detailing.   
 
Although there are many exceptions (West et al, 2005), variations in physician prescribing 
patterns related to antipsychotic medications emphasize the need to improve guidelines 
implementation (Buchanan, et al, 2002; Chen et al, 2000; Leslie & Rosenheck, 2001).   
 
It is the opinion of Delessert et al (2007) that ‘the future certainly belongs to clinical 
practice guidelines, which proposes, in addition to the clinical recommendations 
themselves, a method to check their application in clinical practice’.  
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Chapter 2 – Literature Review 
 
A critical review of the literature of the clinical presentation and the pharmacological 
treatment of schizophrenia, variance in the quality of care and the use of clinical practice 
guidelines now follows. 
 
2.1.  Schizophrenia – clinical presentation and goals of 
treatment  
 
2.1.1  Diagnostic features 
 
Schizophrenia is a chronic illness that influences virtually all aspects of an affected 
person’s life (American Psychiatric Association, 2004).  The Diagnostic and Statistical 
Manual of Mental Disorders IV (DSM IV) diagnostic criteria are given in Appendix A, and it 
will be noted that no single symptom is pathognomonic of the illness; the diagnosis 
involves the recognition of a constellation of signs and symptoms associated with impaired 
occupational or social functioning (American Psychiatric Association, 1994).  
 
Characteristic symptoms may be conceptualized as falling into two broad categories – 
positive and negative.  Positive symptoms of schizophrenia include delusions, 
hallucinations, disorganized speech and grossly disturbed or catatonic behaviour; negative 
symptoms include affective flattening, alogia and avolition. (American Psychiatric 
Association, 1994) 
 
 
2.1.2  Phases of the disorder 
 
The course of the illness for the majority of patients comprises a prodromal period, an 
acute phase, a period of stabilization and a stable phase (American Psychiatric 
Association, 1994).   
 
The acute phase refers to the periods during which the patient experiences an active 
episode of positive symptoms, with either the onset of symptoms after an asymptomatic 
period or a marked increase in symptoms over a baseline of less severe symptoms (Dixon 
et al, 1995).  During an episode some patients suffer extreme changes in their thinking, 
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mood and behaviour.  Many patients will be hospitalised during the acute phase of the 
illness and some patients will be formally detained (Thompson, 1994).  Operationally, this 
phase may be defined as the first 6 to 8 weeks after onset of an episode of positive 
symptoms (Dixon et al, 1995).  After a stabilization period of variable duration, the phase 
of long-term maintenance treatment follows - this refers to the periods during which the 
patient is not experiencing an acute episode as defined above (Dixon et al, 1995)  
 
 
2.1.3  Goals of treatment 
 
The goals of treatment during the acute phase are to prevent harm, control disturbed 
behaviour, reduce the severity of psychosis and associated symptoms (e.g. agitation, 
aggression, negative symptoms, affective symptoms), determine and address the factors 
that led to the occurrence of the acute episode, effect a rapid return to the best level of 
functioning, develop an alliance with the patient and family, formulate short- and long-term 
treatment plans and connect the patient with appropriate aftercare in the community 
(American Psychiatric Association, 2004; Dixon et al, 1995). 
 
During the stabilization phase, the goals of treatment are to reduce stress on the patient 
and provide support to minimize the likelihood of relapse, enhance the patient's adaptation 
to life in the community, facilitate continued reduction in symptoms and consolidation of 
remission and promote the process of recovery (American Psychiatric Association, 2004). 
 
The goals of treatment during the stable (or long-term treatment) phase are to ensure that 
symptom remission or control is sustained, that the patient is maintaining or improving his 
or her level of functioning and quality of life, that increases in symptoms or relapses are 
effectively treated and that monitoring for adverse treatment effects continues (American 
Psychiatric Association, 2004; Dixon et al, 1995; Turner & Stewart, 2006).   
 
 
2.1.2  Associated descriptive features and mental disorders 
 
The individual with schizophrenia may display inappropriate affect, anhedonia), dysphoric 
mood, sleep disturbances and substance abuse.  Completed suicide occurs in about ten 
percent of patients (American Psychiatric Association, 1994). 
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2.2  The pharmacotherapy of schizophrenia 
Schizophrenia is a serious and complex disorder, with treatment requiring a large number 
and wide range of health and social service resources (Tunis et al, 2004).  Despite 
scientific advances in treatment, the efficacy-effectiveness gap is wider for schizophrenia 
than any other serious medical disorder (McGorry, 2005). 
 
An important component of schizophrenia management includes psychosocial treatments 
(Bhanji & Tempier, 2002; Huxley et al, 2000) which serve as an effective adjunct to the 
pharmacotherapy for schizophrenia (Haddock & Lewis, 2005; Patterson & Leeuwenkamp, 
2008).   
 
It is antipsychotic pharmacotherapy, however, that is the cornerstone of effective treatment 
for schizophrenia (Leslie & Rosenheck, 2004; Parker et al, 2002; Thompson, 1994). 
Antipsychotic drugs not only promote functional recovery but also prevent symptom 
relapse (Schooler, 2006) and help manage residual features in patients with chronic 
schizophrenia (Turkington et al, 2006)   
 
 
2.2.1  Antipsychotic drugs 
 
During the acute phase of schizophrenia, antipsychotic medication eliminates or reduces 
the intensity of psychotic experiences (Thompson, 1994).  The majority of patients with 
schizophrenia will get better with treatment for an acute episode and leave hospital, but 
most patients will require maintenance treatment with antipsychotic drugs for some time, 
perhaps indefinitely, in order to prevent a relapse (Thompson, 1994).  The use of 
antipsychotic agents has been shown to reduce the risk of relapse and hospitalization and 
help improve patients' long-term functional outcomes (Lieberman et al, 2005; McEvoy et 
al, 2006; Stroup et al, 2006).   
 
 
2.2.2  Adjunctive medications 
 
Benzodiazepines, anticholinergic drugs, antidepressants, lithium and anticonvulsants  are 
commonly used adjunctive medications (Casey et al, 2003; Chaplin & McGuigan, 1996; 
Ren et al 2005; Siris et al, 1994; Wolkowitz & Pickar, 1991).   
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2.3  Variations in service delivery and quality of care  
The prescribing practices for schizophrenia vary greatly among centres and countries 
(Bitter et al, 2003) and clinical charts are a source of data which may be used to assess 
the quality of health care (Brook et al, 1996).  One approach to improving quality of care is 
to encourage physicians to follow evidence-based practice guidelines (Dickey, 2006). Prior 
to examining several clinical practice guidelines, the conflicting research findings and 
opinions over antipsychotic choice, polypharmacy, dosing, route of administration and 
adjuvant therapy are now explored.   
 
 
2.3.1  Choice of an antipsychotic 
 
Treatment with FGAs is effective, however, adverse drug reactions are common.  Initial 
studies of the efficacy of SGAs found them to be more efficacious than FGAs in symptom 
control (Davis et al, 2003; Turner & Stewart, 2006), specifically in terms of reducing both 
positive and negative symptoms, and in preventing relapse (Kane, 2006; Turner & 
Stewart, 2006).  SGAs were also found to be better tolerated (Geddes, 2002; Leucht et al, 
2003), resulting in a lower incidence of movement disorders including tardive dyskinesia 
(Kane, 2006; Tandon et al, 2008; Turner & Stewart, 2006).  Adherence to treatment was 
also thought to be better - but this issue has remained controversial (Geddes, 2002; 
Leucht et al, 2003).   
 
SGAs are associated with a different profile of adverse reactions, including a higher 
incidence of metabolic side-effects (Tandon et al, 2008), including disturbances in lipid and 
glucose regulation (Volavka & Citrome, 2009) which may result in diabetes (American 
Diabetes Association, 2004; Sernyak et al, 2002) and weight gain (Sernyak et al, 2002; 
Turner & Stewart, 2006).  Despite these potentially serious side-effects, Naber & Lambert 
(2009) believe that the lower risk of tardive dyskinesia and the better subjective effects 
should be strong enough reasons to favour these drugs.   
 
Data from two large, independent, major government-funded studies – ‘Clinical 
Antipsychotic Trials in Intervention Effectiveness’ (CATIE) (Lieberman et al, 2005) and 
‘Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study’ (CUtLASS) (Jones et 
al, 2006) - of  the comparative antipsychotic effectiveness in schizophrenia contradict the 
widely prevalent belief that the SGAs are vastly superior to the FGAs.  Dosing was found 
to be a key variable in optimizing effectiveness of both FGAs and SGAs (Tandon et al, 
2008) and the side-effects of SGAs become more severe as dosages increase, often with 
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little or no increase in effectiveness (Baldessarini et al, 1988; Citrome & Volavka, 2002).  
CATIE and CUtLASS suggest that SGAs, except clozapine in the treatment-resistant 
population, offer little, if any, clinical benefits, and moreover, their side-effects are 
problematic (Foussias & Remington, 2010).  The finding that oral SGAs are no more 
efficacious than FGAs has also been shown in first-episode schizophrenia (Kahn et al, 
2008) and in patients with chronic schizophrenia (Lieberman et al, 2005).  In summary, 
CATIE and CUtLASS showed considerable differences between individual agents and 
overlaps between the two groups in terms of efficacy and side-effects.  Volavka & Citrome 
(2009) consider the classification of antipsychotics into the two groups no longer to be 
useful.  Furthermore, the effectiveness of antipsychotic drugs varies greatly in a real world 
setting. (Tiihonen et al, 2006).  
 
A Cochrane Review of 21 trials comparing the use of haloperidol with placebo in the 
treatment of schizophrenia (or other serious psychotic illness) concluded that the drug has 
a high propensity to cause adverse effects and should be used only if there is no treatment 
option (Irving et al, 2006).   
 
Treatment responsiveness is another factor that should be considered in the selection of 
an antipsychotic drug.  Clozapine is the treatment of choice for patients with treatment-
resistant schizophrenia; such treatment should not be delayed or withheld (Taylor et al, 
2010) 
 
It is clear that there is no single antipsychotic drug that is best for every patient with 
schizophrenia, as individual responses differ markedly.  For successfully individualized 
treatment, a multitude of antipsychotic options are needed (Naber & Lambert, 2009) and 
clinical practice guidelines make recommendations in this regard.   
 
 
2.3.2  Polypharmacy  
 
Polypharmacy – the simultaneous use of multiple psychotropic drugs, be they similar or 
dissimilar - is a very common practice (Ghaem, 2002).  Antidepressants, anti-anxiety 
medications, mood stabilizers and also the concurrent use of two or more antipsychotics 
have been implicated (McCue et al, 2003).  However, rigorous data on combination 
therapy in schizophrenia are rare; some evidence supports a combination of 
antipsychotics and antidepressants for negative symptoms and comorbid major 
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depressive episodes. The add-on of lithium and mood stabilizers lacks compelling 
evidence, but might be beneficial for specific subgroups (Zink et al, 2010) 
 
Antipsychotic polypharmacy - the use of two or more antipsychotic drugs - appears to be 
increasing (Gören et al, 2010; Langan & Shajahan, 2010) despite it not being evidence-
based (Taylor, 2010), is considered to reflect poor prescribing practice (Haw & Stubbs, 
2003) and is condemned by numerous bodies (Taylor, 2010).  Antipsychotic polypharmacy 
is associated with patients receiving depot medication (Barnes et al, 2009) and with 
‘difficult-to-treat’ patients where there is a need for clinical answers but no evidence base 
(Barbui et al, 2006) 
 
The introduction of SGAs has not improved the practice of polypharmacy.  A systematic 
review of studies, case reports and article reviews by Pandurangi & Dalkilic (2008) showed 
that polypharmacy with SGAs is not uncommon, and give a prevalence varying between 
3.9 and 50%, depending on setting and patient population.  SGA polypharmacy may also 
be found in chronic inpatients with severe and persistent mental illness (Megna et al, 
2007).  Combining FGA depot and SGA oral medication has been noted in forensic 
patients who exhibited treatment-resistant illness and to ensure adherence to at least part 
of the treatment (Bains & Nielssen, 2003).  There remains little support for co-prescription 
of antipsychotics but considerable evidence to suggest that such practice worsens 
adverse effect burden.  Co-prescription of SGAs and FGAs should be avoided in all but 
very exceptional circumstances (Taylor et al, 2002)   
 
The problem currently is that the degree of polypharmacy being practiced seems far in 
excess of the supporting data (Kane & Leucht, 2008).  As psychopharmacology becomes 
more sophisticated, the possibilities for both rational and irrational polypharmacy increase 
exponentially (Kingsbury et al, 2001) and many authors contend that antipsychotic 
polypharmacy may be a rational approach in some situations (Correll et al, 2009) 
including: when changing gradually from one drug to another (Thompson, 1994); when a 
second antipsychotic is added to counteract a problem (e.g. safety, tolerance or 
adherence) arising during monotherapy; where the clinician may have serendipitously hit 
upon an effective combination (Miller & Craig, 2002); where there has been failure or 
patient refusal of all reasonable monotherapies (Miller & Craig, 2002; Tapp et al, 2003); in 
treatment-refractory cases for whom it has been proved necessary by experience over 
several years (Thompson, 1994; Zink et al, 2010); where  indefinite continuation of 
combinations initially intended to be brief has occurred  (Ereshefsky, 1999) and in 
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treatment-emergent positive and/or negative symptoms under clozapine monotherapy may 
benefit from adding an SGA (Zink et al, 2010).   
 
It may be true that different antipsychotics are prescribed together because they have 
different effects on different symptoms of psychosis and that polypharmacy may represent 
the optimal application of scientific knowledge and clinical experience combined (Taylor, 
2002).  Physicians may therefore be making a greater effort to ‘fine-tune’ treatment 
response (Clark et al, 2002).  Taylor (2010) believes that targeted evidence-based 
antipsychotic polypharmacy may be the way forward. However, the lack of published data 
makes the practice of using multiple antipsychotic agents a gray area and problematic for 
the clinician (Schumacher, 2003).   
 
 
2.3.3  Drug Dose 
 
Most definitions of optimal treatment for patients with schizophrenia assign a central rôle 
to appropriate antipsychotic medication dosage.  The dose of an antipsychotic that a 
patient will require will depend on several factors including age – older patients generally 
require lower doses and often have more side-effects than younger patients (Thompson, 
1994).   
 
There is evidence that maximum efficacy for typical antipsychotics occurs at 70 – 80% of 
dopamine receptor occupancy and that these levels can be achieved at doses 
substantially lower than was previously thought necessary (Kapur et al, 1996; McEvoy et 
al, 1991; Stone et al, 1995).  Literature reviews have failed to show any clinical benefit in 
prescribing high doses of antipsychotic medications (Davis & Chen, 2004; Freudenreich & 
Goff, 2002) and data from controlled trials indicate that, above a certain threshold, higher 
antipsychotic dosages generally increase the occurrence of side-effects without 
contributing to clinical improvement (McEvoy et al, 1991). 
 
Despite this, the prescription of high-dose antipsychotic medications is a well-documented 
phenomenon, one of the chief reasons for this being antipsychotic polypharmacy (Chaplin 
& McGuigan, 1996; Harrington et al, 2002; Tibaldi, et al, 1997), but this may be inadvertent 
because each individual drug may be within recommended limits (Parket et al, 2002).   
 
Tavernor et al (2000) found that in a secure psychiatric facility, psychosis rather than 
aggression best predicted antipsychotic dose, whereas other authors have found that 
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patients’ history and reputation for violence (not current presentation), treatment non-
responsiveness and duration of illness were the determinants (Bitter et al, 2003; Chaplin & 
McGuigan, 1996; Krakowski et al, 1993; Lelliott et al, 2002; Peralta et al, 1994; Wilkie et 
al, 2001) 
 
Another reason for the use of high-dose antipsychotic treatment is pro re nata (PRN)/‘as 
required’ prescribing (Ito et al, 2005; Paton et al, 2008).  Yet another reason is 
idiosyncratic prescribing by some consultant psychiatrists of dosages that are higher than 
those used by their colleagues, a factor that must be considered when calculating an 
average dose (Wilkie et al, 2001)  
  
Some authors claim that  high-dose treatment is warranted in some instances, despite the 
lack of research evidence to back this up (Mortimer, 1994), however, it is clear that some 
patients are maintained on high-dose treatment unnecessarily contributing to 
extrapyramidal side-effects and mortality due to cardiac conduction abnormalities 
(Glassman & Bigger, 2001; Mehtonen et al, 1991).  
 
A different view is held by Oosthuizen et al (2001) who found that ultra low-doses of 
haloperidol (2mg/day) were effective and well-tolerated in first-episode psychosis.  The 
same findings were again noted by Oosthuizen et al (2004) when ultra low doses of 
haloperidol were compared with high dose haloperidol (8mg/day) in the same condition.  
 
By way of an explanation for these variances, Baldessarini et al (1998) state that there is 
no clear relationship between neuroleptic dose and clinical response.  Young (2003) 
advises that dose is only indirectly related to outcomes, and that some patients have a 
reduction in psychosis at low dosages, while others have no side-effects at high dosages. 
Indeed, certain patients do best at low dosages, and others do best at high dosages.  
 
However, numerous other studies including those by Soher et al (2003) and Owen et al 
(2000) demonstrate that adherence to prescribing guideline dose for antipsychotic 
medication is associated with improvement in patient outcomes following hospital 
discharge – including a lower severity of symptoms at six-month follow up than patients 
who received low or high doses.  
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2.3.4  Route of administration: Depot antipsychotic formulation 
 
Long-acting depot antipsychotics were developed in the 1960s and were specifically 
aimed at promoting treatment adherence in people with chronic illness, thereby enhancing 
relapse prevention (Davis et al, 1994; Kane, et al, 1998; Weiden & Glazer, 1997).  
Prescribing practices for depot antipsychotics differ significantly between countries 
(Dencker & Axelsson, 1996; Sim, K. et al, 2004), within a region and between regions of 
one country (Taylor et al, 1999) 
 
It is generally is accepted that the depot formulations offer a distinct advantage in the 
ability to document and observe non-adherent behaviour (Adams et al, 2001; Marder, 
1986), improve medication adherence (Kane, 2003), benefit non-adherent schizophrenia 
patients (McEvoy, 2006) and facilitate relapse prevention (Kane, 1998).   
 
However, it has been found that depot formulations play a relatively minor rôle in the 
treatment of schizophrenia (Heres et al, 2006).  There may be many reasons for this 
including the belief that depot treatment is associated with a high risk of extrapyramidal 
adverse effects (Barnes & Curson, 1994; Möller, 2007) which may reduce adherence to 
medication and precipitate relapse (Luft & Berent, 2009).  This is disputed by Adams et al 
(2001) who found that when comparing existing depot FGAs with oral preparations of the 
same drug, there was no conclusive difference in extrapyramidal side-effects.  Numerous 
other authors agree with Adams et al (Haddad et al, 2009; Patel et al, 2003; Patel & David, 
2005; Taylor, 2009).  
 
It was hoped that when SGA-depot medication became available, staff and patients would 
re-examine their attitudes (Waddell & Taylor, 2009) and that depot would be used less 
restrictively (Möller, 2007) including in first-episode patients (Chue, 2007).  However, 
psychiatrists continue to use depot antipsychotics in a conservative way although they 
attribute positive traits to the method (Jaeger & Rossler, 2010).  Patel et al, (2010) have 
noted that depot prescribing rates have continued to decrease over the last 5 years.  
Ascher-Svanum et al (2009) and Verhof et al (2008) have noted that patients who receive 
SGA-depot medication tend to be more severely psychotic and that depot is used as a last 
resort.  Interestingly, a study by Heres et al (2006) showed that the main factor for 
opposing both FGA and SGA depot preparations is the clinicians’ assumption that their 
patients were adherent.   
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It is the opinion of Patel & David (2005) that some psychiatrists may not adequately 
consider the risks and benefits when contemplating prescribing depot medication.  Use of 
long-acting preparations in patients with schizophrenia who are medication nonadherent 
remains uncommon despite clinical recommendations urging their use (West et al, 2008).   
 
 
2.3.5  Adjuvant medication 
 
Benzodiazepines 
Benzodiazepines provide significant effects in terms of short-term sedation in the patient 
with acute psychotic agitation (Volz et al, 2007; Wolkowitz & Pickar, 1991) but long-term 
anti-psychotic treatment with benzodiazepines has not shown convincing efficacy (Volz et 
al, 2007).  A review by Wolkowitz & Pickar (1991) showed that anti-psychotic response 
was shown to be highly variable, required high doses and when improvement occurred, it 
diminished within a few weeks. Also, Haw and Stubbs (2007) reported a favourable risk-
benefit ratio for the use of benzodiazepines in certain patients. 
 
In a study by Paton et al (2000) almost one in ten patients occupying rehabilitation beds 
had a diagnosis of schizophrenia and received benzodiazepines in the medium- or long-
term.  Possible reasons for this include inadequate response to antipsychotics alone, an 
‘antipsychotic sparing effect’ of the benzodiazepine, poor review of the drug regimen after 
a period of acute disturbance, misuse by patients and - in the case of PRN medication - 
inappropriate use by staff.  Maintenance benzodiazepine/hypnotic use has been found to 
be common (Meagher & Moran, 2003) 
 
 
Anticholinergic Drugs 
Anticholinergic drugs may be prescribed because first-generation antipsychotics (FGAs) 
are often associated with extrapyramidal symptoms (Ren et al, 2005).  Some SGAs such 
as clozapine, olanzapine, and quetiapine have significant affinity for the muscarinic 
receptors in vitro, while aripiprazole, risperidone, and ziprasidone do not (Chew et al, 
2006).  In a recent study of over 5 000 patients receiving SGAs, Eisen et al (2008) found 
that despite the milder side-effect profile of this class of drug, over 1 400 patients received 
anticholinergic medication which may reflect overuse.  
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Mood stabilizers  
The off-label prescription of mood stabilizers is very common in psychiatry (Haw & Stubbs, 
2005), however, neither in monotherapy nor as adjunctive agents to antipsychotics do 
these drugs have a beneficial effect that is well-supported in the literature (Berle & 
Spigset, 2005; Dussias et al, 2010). They could be considered as potential adjuncts to 
antipsychotics in patients with treatment-resistant schizophrenia, although the 
documentation is sparse (Berle & Spigset, 2005).  Leucht et al (2002) examined trials of 
carbamazepine as an adjunctive drug in the treatment of schizophrenia but could find no 
statistically significant benefit.  Mood stabilisers have not been found to be a useful 
treatment strategy for improving the residual symptoms of schizophrenia (Glick et al, 
2009).   
 
 
 
2.4  The use of prescribing data in routine clinical settings 
 
2.4.1 The need for studies in routine clinical settings 
 
In comparison with hundreds of randomized clinical trials of various pharmacological and 
psychosocial treatments for schizophrenia, there are relatively few studies of the treatment 
patterns in routine care settings (Mojtabai et al, 2009).  In clinical settings, many factors 
related to the patient, the provider and the treatment setting influence medication 
decisions, but these influences are minimized in the clinical trial design (Soher et al, 2003).  
 
Another reason for studying patterns and outcomes of treatments in every-day practice is 
because of concerns that recommended evidence-based treatments may not be 
effective for a significant portion of patients in routine practice (Zarin et al, 1998). 
 
2.4.2  The value of collecting prescribing data 
 
There are no routinely collected prescribing data that allow for the quality of prescribing for 
psychiatric patients to be monitored (Paton & Lelliott, 2004).  It should be noted that 
indicators cannot cover all facets of the care provided to patients, nor can they include the 
complexity of environmental and personal aspects - the indicators represent a minimal set 
of requirement to be met in the care of patients with psychosis, and several indicators of 
prescribing quality in psychiatry have been proposed (Bollini et al, 2008).     
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The assumption is that prescribing within the parameter represents good practice and the 
converse thereof (Paton & Lelliott, 2004). Of relevance to this study are the indicators that 
reflect a categorical concept – that is, whether prescribing for an individual patient is within 
or outside a stated parameter.  A number of these have been identified, viz. high dose 
antipsychotic (Harrington et al, 2002; Moran et al, 2006; Paton & Lelliott, 2004), 
antipsychotic polypharmacy (Harrington et al, 2002; Moran et al, 2006; Paton & Lelliott, 
2004), SGA polypharmacy (Paton & Lelliott, 2004), multiple PRN prescribing (Birmingham 
et al, 1999; Paton & Lelliott, 2004), low dose mood stabilisers (Paton & Lelliott, 2004), 
maintenance (long-term) hypnotic use (especially benzodiazepines) (Mahomed & Paton, 
2002; Paton & Lelliott, 2004), polypharmacy (the use of two agents of the same class) 
(Moran et al, 2006), the routine use of anticholinergic agents (Moran et al, 2006) and the 
avoidance of drug interactions (Williams et al, 2000).  
 
Recommendations for many of these parameters are specifically addressed in the six 
clinical practice guidelines that are used in this study. 
 
According to Paton & Lelliott (2004), it seems likely that prescribing will be monitored using 
indicators of this type.  If this is the case, those responsible for using prescribing indicator 
scores must understand how difficult they are to interpret.  When differences between 
prescribers or groups of prescribers are found, a number of questions should be posed 
before asking them to review their practice, including case mix and service level factors 
that might influence prescriber decision making. 
 
 
 
2.5  Clinical Practice Guidelines  
 
2.5.1  The value of clinical practice guidelines in improving the quality of care  
 
A common concern underlying the measurement of the quality of treatment is that patients 
with psychosis are very vulnerable and have limited advocacy capacity, and are therefore 
at risk of inadequate care or even neglect (McAlpine & Mechanic, 2000; McNulty et al, 
2003; Lehman, 1998).  One way to improve the quality of care is by the use of evidence-
based clinical practice guidelines (Grims & Russell, 1993; Miller & Kearney, 2004).   
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Evidence-based medicine has been defined as ‘the integration of best research evidence 
with clinical expertise and patients’ values (Sackett et al, 2000).  It differs from the 
traditional approach to healthcare in that in addition to relying on clinical experience, 
expert opinion and knowledge, clinicians apply research evidence to individual patients in 
a way that takes into account their particular experiences, expectations and values 
(Bhandari et al, 2004).  The clinical trial is the linchpin of evidence-based medicine (Kane 
& Leucht, 2008), however, the large gap between evidence generated in the highly 
controlled paradigms of evidence-based medicine and the reality of everyday practice has 
been highlighted for research attention (Moran et al, 2006). 
 
Evidence-based guideline development can reduce the delivery of inappropriate care 
(Goel & Trivedi, 2007; Grol et al, 1999; Mellman et al, 2001; Merritt et al, 1997) and 
achieve more uniformity in the way that people with a certain condition are managed (Goel 
& Trivedi, 2007; Rowlands, 2004).  The quality of mental healthcare and treatment has 
been significantly improved in the last decade by the use of clinical practice guidelines 
(Grol & van Weel, 2009; Jakovljević 2007).   
 
Treatment decisions are also typically evaluated by comparing them against norms, such 
as practice guidelines (Falzer & Garman, 2010).  Proponents believe that clinical practice 
guidelines provide a guide to best practice for use as a benchmark against which to 
evaluate clinical practice (Turner et al, 2009) and higher adherence rates are used as 
evidence of better quality of care (Walker, et al, 2004; Lohr, 1990). There is growing 
interest in the use of prescribing indicators (specifically) to evaluate care processes and 
measure the performance of mental health services (Goel & Trivedi, 2007; Paton & Lelliott, 
2004).  
 
Other authors caution that there are problems with converting clinical practice guidelines 
into performance measures because outcomes are associated with a complex interplay 
among social context, availability of resources and treatment decisions in addition to 
medication use (Davidowitz et al, 2004) and a more balanced perspective is required 
(Rabinowitz et al, 1999).  Adherence to practice guidelines has therefore been criticized as 
inappropriate, but no measurable alternative has been proposed to date (Falzer & 
Garman, 2010). 
 
Furthermore, although it has been shown in rigorous evaluations that clinical practice 
guidelines can improve the quality of care (Grimshaw & Russell, 1993), whether they 
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achieve this in daily practice is less clear.  This is partly because patients, doctors, payers 
and managers define quality differently (Woolf et al, 1999).   
 
Other concerns about clinical practice guidelines include that they may rapidly become out 
of date (Weiden  & Dixon, 1999), be unrealistic in many treatment situations and 
unaffordable to implement (Gaebel et al, 2005), be used by healthcare financers to 
prevent clinicians from deviating from ‘approved practice’, be biased in promoting one 
narrow aspect of a complex issue, they may result in liability concerns (Bhanji & Tempier, 
2002), most do not discuss the minimal training needed to use them (Weiden & Dixon, 
1999), they may lead to ‘cookbook’ medicine and the absence of individualized treatment 
plans (Dixon, 2004) and vary considerably in quality (Boluyt et al, 2005; Cates et al, 2006; 
Christiaens et al, 2004; de Haas et al, 2007; Saturno et al, 2003). 
 
 
 
2.5.2  Setting, context and cultural issues 
 
Practice guidelines have to be based on – or to consider adequately – scientific evidence 
with regard to key treatment recommendations (McIntyre, 2002).  As schizophrenia shows 
a highly variable course in different countries, possibly due to cultural influences (Alem et 
al, 2009; Jablensky et al, 1992) cross-cultural differences must also be reflected in 
schizophrenia guidelines, but it is not clear how this may be done (Gaebel et al, 2005).  No 
validated process for the adaptation of guidelines produced in one cultural and 
organisational setting for use in another (i.e. trans-contextual adaptation) was found in the 
literature by Fervers et al (2006) who state that this is increasingly being considered as an 
alternative to de novo guideline development. 
 
Normative and cultural opinions about the value of specific performance often play an 
important rôle in defining recommendations for practice without making these explicit (De 
Kort et al, 2009; Wollersheim, 2009).  Despite a large number of systematic reviews of 
implementation interventions, many of the fundamental questions regarding what 
approaches should be used in which settings and for which problems remain unanswered 
(Bhattacharyya et al, 2009).   
 
In South Africa there is often a difference in ethnic background between clinician and 
patient, a factor that could lead to mistaken assumptions that affects the way in which 
clinicians adhere to guidelines or make treatment decisions (Herbeck et al, 2004; Kuno & 
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Rothbard, 2002; Segal et al, 1996).  According to Koen et al (2008), in the interests of 
mental health care in South Africa, it is becoming necessary for us to implement practical 
clinical guidelines, and make these readily available in the large variety of settings that 
characterize this country.    
 
 
2.5.3  History, methodology and application of the guidelines used in the study 
 
Six of the best known English-language clinical practice guidelines for the treatment of 
schizophrenia were included in the study.  Each is from a country where English is either 
the primary language or the lingua franca, and include two from the United States (one 
guideline is research-based and the other a consensus of expert opinion), Canada, 
Australia and New Zealand, the United Kingdom and South Africa.   
 
When the American Psychiatric Association Schizophrenia Guideline project began, no 
other comprehensive treatment guidelines were available (Weiden & Dixon, 1999).  The 
Association had published its American Psychiatric Association guidelines (APAGs) in 
1997 and the review of this evidence published by this group was used to varying extents 
by other groups such as the one from Canada that produced the Canadian Clinical 
Practice Guidelines (CCPGs) (Bassett & Addington, 1998).  Their shared background 
information resulted in very few discrepancies between these two guidelines, however, the 
goals of the organisations that produced them differed in that they aimed to reflect local 
practices as well as provide increased specificity to the guidelines (Bhanji & Tempier, 
2002).  The APAGs are supported by the political weight of the American Psychiatric 
Association, conferring a de facto authority, and are considered the closest to establishing 
a standard of practice (Weiden & Dixon, 1999). 
 
By their very nature, the APAGs and CCPGs lag behind clinical practice and the Expert 
Consensus Guidelines (ECGs) that were developed by a panel of clinical experts to 
address important clinical questions unanswered in the research literature.  The major 
advantage to the ECGs (updated in 1999 and also produced in the United States) is that 
they were relatively comprehensive and current in areas of pressing clinical concern at the 
time, however, the inherent disadvantage is that the ECGs are recommendations are 
based on opinions, not sound, scientific research data (Weiden & Dixon, 1999).   
 
Guidelines have existed in England for decades (Woolf et al, 1999). The guidelines issued 
by the National Institute for Clinical Excellence (NICE) in the United Kingdom were the 
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result of collaboration by professionals from various disciplines, service users and carers 
(Rowlands, 2004).  The NICE guidelines (NICEGs) were updated in 2009. 
 
  
2.5.4  Comparative evaluation of clinical practice guidelines 
 
Gaebel et al (2005) compared twenty-seven national schizophrenia guidelines from 
different countries and found recommendations for pharmacotherapy to be similar.  
However, Bhanji & Tempier (2002) are of the opinion that discrepancies between 
guidelines are noteworthy because clinical practice guidelines are designed to reduce 
variations in practice patterns.  There is still disagreement among the various experts 
(Bhanji & Tempier, 2002). 
 
 
2.6.  Overview of literature review 
A review of the pertinent literature was undertaken in order to gain better insight into the 
pharmacotherapy of schizophrenia.  
 
The diagnostic criteria for schizophrenia, the phases of the disorder and the goals of 
treatment were explored as were the numerous antipsychotic and other drug therapies 
available to the psychiatrist. 
 
The review revealed suboptimal prescribing practices to be a frequent finding in routine 
practice.  These included irrational polypharmacy (including antipsychotic polypharmacy); 
the underuse of depot antipsychotic drugs; the inappropriate manner in which 
anticholinergic agents and benzodiazepine sedatives were used; and the problems of PRN 
and high dose prescribing.   
 
The rôle of clinical practice guidelines was explored and drivers for their development 
were identified. These include drug-innovation; the need for the improved management of 
side-effects; rising costs; variance in service delivery and the potential for harm; 
information overload; changes in treatment goals and the management of antipsychotic 
non-adherence.  The advantages and disadvantages of using clinical practice guidelines 
were reviewed, and the need for further studies of prescribing practices in routine clinical 
settings was noted.   
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The literature review prompted the question ‘to what extent do the prescribing patterns at 
the hospital at which the study was conducted adhere to the relevant clinical practice 
guidelines in the pharmacotherapy of schizophrenia?’  - a question that this study 
attempted to answer. 
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Chapter 3 – Methodology 
 
The study design, strategy of inquiry, instrumentation, target and sample populations and 
data analysis are now presented. 
 
3.1. Study Design 
The analysis of current patterns of care by the use of routine data from electronic patient 
records or clinical registries may help highlight deficiencies in actual care (Hoelzer et al, 
1999).  The ‘chart review’ study design has been used successfully to extract relevant data 
in a number of psychiatric studies (Baldassano et al, 2004; Barzman et al, 2004; Bloch et 
al, 2005; Dworkin, 1987; Henderson et al, 2004; Staller, 2004), and retrospective chart 
reviews have been used to determine whether current guidelines are being followed 
(Remington et al, 2001).     
 
A descriptive, retrospective, three-times sampling, cross-sectional, chart review was 
considered a suitable design to compare the prescribing of psychotropic medication with 
six clinical practice guidelines.  If the results of this study prove to be a source of concern, 
the findings may be used by other researchers to generate a testable hypothesis.  
 
 
3.1.1. Advantages of the study design 
 
Chart reviews offer a relatively inexpensive way to research the rich readily accessible 
existing data (Gearing et al, 2006), there is no workload for hospital staff, no 
inconvenience for departments or interruptions of the health-care process, and the data 
collection is easy to plan and execute (Michel et al, 2004). Cross-sectional studies are 
usually used to determine the prevalence of variables under study - for example: a 
condition (Mann, 2003).  A particularly useful application of a retrospective study is as a 
pilot study that is completed in anticipation of a prospective study. A retrospective study 
can help to focus the study question, clarify the hypothesis, determine an appropriate 
sample size and identify feasibility issues for such a prospective study (Hess, 2004).   
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3.1.2 Disadvantages of the study design 
 
There are, however, disadvantages of the design: it is not possible to distinguish the 
patients by severity of illness or to identify precisely why certain approaches to treatment 
were undertaken (Remington et al, 2001).  Acquisition of adequate patient data for clinical 
management is hard enough, but higher quality patient data are needed for clinical audit 
and research (Wyatt, 1995).  Furthermore, in retrospective chart reviews, missing data can 
result in a hidden or non-response bias in the results (Worster & Haines, 2004). 
 
 
3.2.  Recommendations made in six clinical practice 
guidelines for the pharmacological management of 
schizophrenia. 
Many of the original guidelines for the pharmacotherapy of schizophrenia have been 
updated and the most recent versions were used in the study.  The six guidelines included 
are: the Expert Consensus Guidelines (ECGs) (McEvoy et al, 1999), the Canadian Clinical 
Practice Guidelines (CCPGs) (Addington et al, 2005), the Australian and New Zealand 
Guidelines (ANZGs) (McGorry, 2005), the National Institute for Clinical Excellence 
Guidelines (NICEGs) (NICE, 2009), the American Psychiatric Association Guidelines 
(APAGs) (American Psychiatric Association, 2004) and the South African Guidelines 
(RSAGs) (Stein et al, 2005) 
 
A brief overview of the parameters that are considered in this study now follows.  The 
reader is referred to the tables in Appendix B for more detail on the topics.  All dosages 
are in milligrams per day - unless otherwise stated.  Where no advice is given in a 
guideline, no comment was made. 
 
 
3.2.1  Emergency management – choice of drug and drug dose - Appendix B - Table 
1 
 
SGAs are recommended as the first choice by CCPGs, ANZGs, NICEGs and APAGs, with 
or without benzodiazepines (ANZGs and APAGs).  FGAs are given as an option in 
NICEGs and APAGs but are advised against by ANZGs; zuclopenthixol may be 
considered (CCPGs) and ‘rapid neuroleptisation’ is to be avoided (NICEGs).  If the patient 
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accepts oral medication, this is preferred; if not, parenteral administration may be 
necessary (ANZGs, APAGs).  Suggested doses include:  olanzapine 10 (CCPGs); 
lorazepam 1-2, diazepam 5-10; olanzapine 5-10,quetiapine 50-100 (ANZGs).  If the patient 
is combative, midazolam 5, clonazepam 0.5-2, may be used (ANZGs). 
 
 
3.2.2  Acute phase (non-emergency) in first episode patient – Appendix B - Table 2 
 
SGAs are the drugs of first choice (ECGs, CCPGs, ANZGs and RSAGs) and also the 
second choice (ANZGs).  Either SGAs or FGAs are the first choice (NICEGs) and may be 
used as first-line therapy in South Africa where SGAs may not be available (RSAGs). 
Benzodiazepines are suggested to control agitation while antipsychotic dose is titrated 
(CCPGs).  See Appendix B for the starting, target and maximum daily doses of 
haloperidol, olanzapine, quetiapine, risperidone, ziprasidone, amisulpride and aripiprazole 
are given (ECGs, CCPGs, and ANZGs).  Dosages may be titrated at not less than weekly 
intervals (CCPGs, ANZGs) and if poor response increased over four weeks to maximum 
dose (ANZGs).   
 
 
3.2.3  Acute phase pharmacotherapy (non-emergency) in multiple episode patient - 
Appendix B - Table 3  
 
SGAs are recommended as first-line treatment (ECGs, CCPGs, APAGs and RSAGs), 
however, APAGs acknowledge that FGAs may be appropriate for individual patients.  
NICEGs recommended either class as the patients’ circumstances dictate.  Switching from 
FGAs to SGAs is generally recommended if the patient has relapsed while on FGAs or 
there are efficacy or tolerability problems (ECGs and ANZGs).  FGAs are recommended if 
there are tolerability problems on SGAs (ANZGs) or if they are unavailable (RSAGs), 
whereas FGA-depot is considered to be the last resort (ECGs).  In the event of treatment-
resistance, switch to clozapine (ANZGs).  See Appendix B for the starting, average and 
maximum doses of haloperidol, olanzapine, quetiapine, risperidone, ziprasidone (ECGs 
and CCPGs).  An adequate length of a trial on ‘adequate’ or ‘optimum’ doses of a drug is 
six to seven weeks (ECGs), four to eight weeks (CCPGs), four to six weeks (NICEGs), two 
weeks to six months (APAGs).  It will be noted that the dosages recommended in the 
multiple episode patient are higher than in the patient with first-episode schizophrenia. 
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3.2.4  Stabilization phase pharmacotherapy- Appendix B - Table 4 
 
Controlled trials have provided relatively little guidance for medication treatment during this 
phase (APAGs).  Depression is common during this phase and an antidepressant may be 
required, medications used for short-term control of agitated behaviour during the acute 
phase may be inappropriate, and the use of depot formulations should be considered to 
reduce medication non-compliance (CCPGs). 
 
 
3.2.5  Stable phase pharmacotherapy- Appendix B - Table 5 
 
SGAs are recommended by ECGs and CCPGs) and FGA or SGA by APAGs.  
Monotherapy is advised by all.  The CCPGs state that there is a high level of individual 
variability in the dose of antipsychotic required in this phase.  Anticholinergic prophylaxis 
for extrapyramidal side-effects is not recommended by some guidelines (ECGs and 
APAGs) but permitted by APAGs. 
 
 
3.2.6  Pharmacotherapy if inadequate response to treatment – Appendix B - Table 6 
 
If the inadequate response was to an FGA, switching to an SGA is recommended or 
implied in all six of the guidelines used in this study.  If the first drug was an SGA, 
increasing the dose – if tolerated by the patient - is recommended for a short period such 
as two to four weeks (ECGs and APAGs).  Adjunctive therapy (e.g. lithium) is considered 
to be an option (ANZGs), a trial of an agent with a unique structure and mechanism is also 
suggested (RSAGs), and if poor adherence is noted, an SGA-depot is advised (ANZGs).  
All guidelines agree that if sequential trials of FGAs and SGAs have been attempted 
without success, switching to clozapine is the appropriate course of action.  If clozapine 
alone is unsuccessful, antipsychotic polypharmacy may be attempted; such an 
augmentation may be needed up to eight to ten weeks, and an agent that does not 
compound the common side-effects of clozapine should be used (NICEGs).  Where 
severe symptoms are refractory to medication, electroconvulsive therapy should be 
considered (RSAGs). 
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3.2.7  Pharmacological management of symptoms associated with psychosis – 
Appendix B - Table 7 
 
For aggression/violence, clozapine is recommended (ECGs, CCPGs and APAGs), high 
potency FGAs and valproate (ECGs), or the use of mood stabilizers and beta-blockers 
(APAGs). 
For agitation/excitement, benzodiazepines are advised (CCPGs, ANZGs and APAGs). 
For insomnia, benzodiazepines (ANZGs and APAGs), a sedating antidepressant such as 
trazodone or mirtazepine (APAGs) or SGA or low-potency FGA (ECGs) are suggested. 
For dysphoria/depression, recommended are selective serotonin reuptake inhibitors 
(SSRIs) (ECGs), ‘antidepressants’ (CCPGs, ANZGs and APAGs), SGAs (ECGs and 
CCPGs) and mood stabilizers (ANZGs). 
Suicidal behaviour may be managed with SGAs (ECGs and CCPGs), clozapine (ANZGs 
and APAGs), and if psychotic depression is present, an SSRI is recommended. 
 
 
3.2.8  Pharmacological management of extrapyramidal side-effects – Appendix B -  
Table 8 
 
The CCPGs guidelines state that when used in the recommended dosage range, risks of 
neurological effects from SGAs are minimal, and that anticholinergic medication is usually 
not recommended with their use.  If akathisia is present, however, the use of a 
benzodiazepine or beta-blocker is advised if dosage reduction is insufficient.  Akathisia 
may also be relieved by benzodiazepines, beta-blockers (RSAGs), diphenhydramine and 
amantadine (APAGs).  For mild tardive dyskinesia, switching from an FGA to an SGA is 
advised (ECGs and APAGs), but if severe, clozapine could be used (ECT and APAGs).  
Other extrapyramidal adverse effects may be managed by antipsychotic dose-reduction or 
switching from high- to low-potency FGAs, or by switching from an FGA to an SGA 
(RSAGs).  
 
 
3.2.9  Depot formulation – Appendix B - Table 9 
  
Depot use should be considered for patients who prefer it, those who have trouble taking 
oral medication reliably and for patients with partial or full non-adherence to 
pharmacological treatment (ECGs, ANZGs, NICEGs, APAGs and RSAGs).  The depot 
form of the same oral medication should be used (APAGS).  The transition from oral to 
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depot treatment can begin during the acute phase but it is not a substitute for the acute 
psychotic episode as it can take months to reach a steady-state (APAGs).   
 
 
3.2.10  Polypharmacy – Appendix B - Table 10 
 
Non-antipsychotic polypharmacy is often appropriate where it may be justified by co-
morbid symptoms.  Antipsychotic polypharmacy, however, is strongly discouraged, but 
considered acceptable under certain circumstances: if switching is in progress (ANZGs 
and NICEGs), if a patient becomes acutely psychotic while on depot treatment it may be 
useful to supplement it with oral medication for a temporary period (APAGs), and (as 
indicated above) if clozapine alone is unsuccessful another antipsychotic may be added.  
The CCPGs guidelines suggest that clozapine may be augmented with lithium, 
anticonvulsants, antidepressants, benzodiazepines and electro-convulsive therapy.  If 
clozapine alone is unsuccessful, antipsychotic polypharmacy may be attempted; such an 
augmentation may be needed up to eight to ten weeks, and an agent that does not 
compound the common side-effects of clozapine should be used (NICEGs).   
 
 
 
3.3.  Strategy of inquiry, data collection and instrumentation 
In a retrospective chart review, sampling refers to the method by which study cases or 
records are selected from the target population or database (Worster & Haines, 2004). 
 
 
3.2.1 Data Collection method/s – Instrumentation 
 
Data was collected using structured record reviews, the data abstraction instrument having 
been designed specifically for the study - see 'Appendix C'. 
 
 
3.2.2 Target and sample populations 
 
The target population included all non-forensic patients between 18 and 65 years of age 
with the diagnosis of schizophrenia and who were prescribed antipsychotic medication 
during their hospital stay and upon hospital discharge.  The sample population included all 
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non-forensic patients between 18 and 65 years of age with the diagnosis of schizophrenia, 
who were admitted to the hospital between September 2007 and September 2010 and 
who were prescribed antipsychotic medication both during their hospital stay (for two 
months or longer) and upon hospital discharge.  This three year period was chosen to 
ensure that all the patients in the study were treated with the same range of psychotropic 
medication which had been made available in September 2007 by the Department of 
Health, according to Circular Letter Number 35 of 2007.  The formulary of relevant drugs 
used in the study is given in ‘Appendix D’. 
 
 
3.2.3 Sampling type and method 
 
Given that the clinical practice guidelines that were examined make recommendations with 
respect to the phases of schizophrenia (emergency, acute and stabilization/stable) three 
data collection points were chosen which correspond roughly to the prescriptions written 
for patients upon admission, at fourteen days and upon hospital discharge.  Another 
reason why sampling at more than one point is required is to examine the use of 
polypharmacy; Miller & Craig (2002) explain that a single cross-sectional analysis of 
frequency of use of combination antipsychotics does not distinguish between short- and 
long-term use. 
 
A study of the prescribing for a patient upon hospital discharge has merit.  Soher et al 
(2003) found that treatment falling within antipsychotic medication dosage guidelines upon 
hospital discharge was associated with improvement in a limited, but critical range of 
short-term patient outcomes.  Furthermore, a study by Young et al (1998) showed that 
many schizophrenic patients received poor-quality care at outpatient clinics and that most 
poor care was due to factors that could be modified 
 
A minimum period of hospital stay of two months or longer was decided upon.  Missing 
values were treated by deleting the case - which according to Dworkin (1987) and Worster 
and Haines (2004) is an acceptable method of dealing with this – and selecting another 
 
A non-probability, purpose, sampling method was used to select the subjects.  The chief 
clerk at the patients’ registry used the computerized information system to search the 
patients’ database for the files (containing the prescriptions) of all patients according to 
diagnostic code for schizophrenia.  The files were then drawn and the inclusion and 
exclusion criteria were applied to determine if the patients’ prescribing details were 
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appropriate for inclusion into the study.  If not, the file was replaced and the next was 
assessed.  The prescriptions of all eligible patients were examined at the three data 
collection points were examined and details of all psychotropic (only) medication was 
noted, including: drug class, route of administration, drug name, dosage and whether 
given routinely or as required (‘pro re nata’ or ‘PRN’ for short).  Medication for physical 
disorders was not recorded. 
 
 
3.2.4 Inclusion criteria 
 
Patients between the ages of 18 and 65 years with the diagnosis of schizophrenia, and 
who were hospitalized for a period of two months or longer, and were treated with 
antipsychotic medication during hospital stay and upon discharge were be included in the 
study.  
 
 
3.2.5 Exclusion criteria 
 
Forensic patients were excluded from the study, as were patients under the age of 18 
years and over the age of 65 years.  Also excluded were patients with schizoaffective 
disorder and those who had been hospitalised for a period shorter than two months.  
 
 
3.4.  Data Abstraction 
The following information was recorded: the duration of hospital stay and details of all 
psychotropic medication prescribed upon admission and discharge of the patient.  The 
class, name, dose, route of administration (orally or by depot injection) and if administered 
routinely or PRN, of each psychiatric drug (only) was noted.  
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3.5.  Data Analysis 
The use of the following prescribing indicators that were highlighted in the six clinical 
practice guidelines were examined at the three data collection points described. 
 
3.5.1 Antipsychotic drugs 
 
- Oral FGAs vs. SGAs 
- Rapid neuroleptisation/tranquilization 
- Antipsychotic polypharmacy (either the concurrent use of depot and oral 
 antipsychotic medication or more than one oral drug – including SGAs)  
- High dose antipsychotic therapy (either from the prescription of a single  antipsychotic in 
a dose that is above the recommended maximum, or two or more antipsychotics 
that, when expressed as a percentage of their respective maximum recommended 
doses and added together, result in a cumulative dose of >100%).  Both the mean 
and median dosages of antipsychotic and other drugs were used given that use of 
the mean dose only may result in spurious conclusions. 
- PRN antipsychotic sedation 
- Depot antipsychotic drugs 
 
 
3.5.2  Anticholinergic drugs 
 
- Choice 
- Dose 
- Anticholinergic medication with SGAs (i.e. in the absence of FGAs) 
- Prophylactic and routine prescribing of anticholinergic drugs 
 
 
3.5.3  Sedative drugs 
 
- Choice 
- Dose 
- Prolonged use of sedative drugs 
- Irrational polypharmacy of other psychotropic medication (e.g. the use of two 
 benzodiazepines) 
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3.5.4  Choice and dose of adjuvant and other drugs 
 
- Antidepressants 
- Lithium 
- Anticonvulsants 
 
The descriptive nature of this study and basic statistics that will be used (e.g. percentages) 
does not warrant the services of a statistician. 
 
 
3.6 Summary of methodology 
The methodology comprised an anonymous, descriptive, retrospective, three-times 
sampled, cross-sectional, chart review of the psychotropic medication prescribed for all 
patients with the diagnosis of schizophrenia who were admitted and discharged from the 
hospital between September 2007 and September 2010 and who were given antipsychotic 
treatment during hospital stay and upon hospital discharge.  Data about the drug class, 
choice, dose, duration, route of administration and whether given routinely or PRN were 
analysed and compared with the recommendations made in six clinical practice guidelines 
for the pharmacological treatment of schizophrenia. 
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Chapter 4 - Results 
 
A description of the findings at each of the three sampling points – on admission, after 
fourteen days and on hospital discharge – now follows 
 
4.1.  Prescribing on hospital admission – first- and multiple- 
episode patient numbers combined 
In this study, the patients admitted to the hospital were either newly referred from the 
psychiatric unit at one of a large number of general hospitals in the geographic catchment 
area that is served by the Facility or had previously been treated there.  Many patients had 
been detained for treatment, having been assessed as dangerous towards themselves or 
others and/or were found to be unable to care for themselves or manage their own affairs.  
Upon arrival, some patients had already been medicated with antipsychotic and other 
psychotropic drugs - medication that might have been continued for several days before/if 
a change was made during their stay in hospital.  A comparison of the medication received 
by this diverse group of patients presenting for admission may therefore not necessarily 
reflect the quality of prescribing at the hospital.   
 
There are, however, a number of findings that may be relevant both on their own and 
when compared with prescription chart sampling at fourteen days following admission and 
again upon hospital discharge. 
 
 
4.1.1.  Antipsychotic drug prescribing on admission  
 
Choice of antipsychotic drug on admission 
From Table 4.1.1.1 ‘Choice of antipsychotic drug/s on admission’ it will be noted that the 
orally administered FGAs that were prescribed to patients admitted to the hospital included 
haloperidol, trifluoperazine and chlorpromazine; the oral SGAs were risperidone and 
clozapine; and the depot antipsychotic zuclopenthixol.  Of the 70 patients in the study, 58 
(82.8%) were prescribed FGAs exclusively on a routine basis (haloperidol was chosen in 
56 (80%) cases, chlorpromazine in 1 and trifluoperazine in the remaining 1).  Eleven 
patients (15.7%) received SGAs routinely (risperidone was used on 10 occasions and 
clozapine on 1).  Only 1 patient (1,4%) was not prescribed an antipsychotic drug for 
routine use. 
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Also noted in Table 4.1.1.1 is that 2 patients were prescribed a combination of an oral 
FGA and a depot FGA (trifluoperazine with zuclopenthixol for one and haloperidol and 
zuclopenthixol for the other). 
 
 
Table 4.1.1.1.  Choice of antipsychotic drug on admission  
 
Drug class and 
route/ N = 
number of 
patients on the 
drug 
Drug name Mono- / poly- 
therapy 
Number of 
patients on the 
drug 
Percentage 
 
 
 
FGA (oral)  
N=58 (82.8%) 
 
 
haloperidol 
N=56 (80%) 
monotherapy 
 
53 75.7 
with prn 
clothiapine 
2 2.8 
with depot 
zuclopenthixol*  
1 1.4 
chlorpromazine monotherapy 
 
1 1.4 
trifluoperazine with depot 
zuclopenthixol** 
1 1.4 
 
 
SGA (oral) 
N=11 (15.7%) 
 
risperidone 
N=10 (14.3%) 
Monotherapy 
 
9 12.8 
with PRN 
clothiapine 
1 1.4 
clozapine with PRN 
clothiapine 
1 1.4 
No antipsychotic 
 
1 1.4 
 
Totals N=70 
 
70 
 
100 
For depot use – see * and ** 
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Dose of antipsychotic drug on admission 
 
Table 4.1.1.2 ‘Dosage parameters of the two most frequently prescribed antipsychotic 
drugs on admission’ shows the number of patients who received the two most commonly 
prescribed antipsychotics for monotherapy.  Haloperidol antipsychotic monotherapy was 
given to 51 (72.8%) patients, with an average dose of 4.8mg/d, a standard deviation of 
0.83, with a dose range of 2.5mg/d to 7.5mg/d and a median dose of 5mg/d.  Eight 
patients received risperidone antipsychotic monotherapy at an average dose of 4mg/d, 
with a standard deviation of 2, a dose range of 2mg to 6mg/d and a median dose of 
4mg/d.  The average and median doses of haloperidol differed by only 0.2mg/d and the 
average and median doses of risperidone were identical. 
 
Chlorpromazine was used for 1 patient with a dosage of 200mg/d, trifluoperazine was 
given to 1 patient at a dosage of 5mg/d and the patient who was receiving clozapine was 
prescribed a dose of 525mg/d.   
 
Of the 2 patients who received zuclopenthixol depot medication in addition to an 
antipsychotic to be taken orally, average dosages were calculated to be 37.5mg/wk 
(milligrammes per week) and 50mg/wk. 
 
 
Table 4.1.1.2.  Dosage parameters of the two most frequently prescribed oral 
antipsychotic drugs on admission  
Drug 
name 
mono- 
poly- 
therapy 
Number 
of 
patients 
on drug 
Percent
-age 
Average 
dose 
(mg/d) 
SD*  
of 
dose 
Range 
of 
dose 
(mg) 
 
Median 
dose 
(mg/d) 
haloperidol mono- 
therapy 
51 72.8 4.8 0.8 2.5 - 
7.5 
5 
risperidone mono-
therapy 
9 12.8 4 2 2 - 6 4 
* standard deviation 
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4.1.2.  Anticholinergic drug prescribing on admission  
 
Choice of anticholinergic drug on admission 
As will be noted from table 4.1.2 ‘Anticholinergic drug prescribing on admission’, 
orphenadrine and biperiden were the only anticholinergic drugs used for newly admitted 
patients.  Ten (14.2%) patients were prescribed anticholinergic medication for routine use 
(orphenadrine to 9 i.e. 12.8% patients and biperiden to the remaining 1).  There were no 
prescriptions for the use of anticholinergic medication for use on a PRN basis.   
 
 
Dose of anticholinergic drug on admission 
 
Table 4.1.2 also shows that the both the mean and median doses of orphenadrine 
prescribed for the 9 patients was 100mg/d with a dose range from 50mg/d to 150mg/d.  
The patient who received biperiden was given a dose of 6mg/d.  
 
 
Table 4.1.2.  Anticholinergic drug prescribing on admission  
Drug name Number 
of 
patients 
on drug 
Per-
centage 
Mean dose 
(mg/d) 
SD* of 
dose 
Range 
of 
dose 
 
Median 
dose 
(mg/d) 
Orphenadrine 
 
9 12.8 100 35.3 50-150 
 
100 
Biperiden 
 
1 1.4 6 - - - 
No anti-
cholinergic drug  
60 85.7 - - - - 
 
Totals N=70 
 
70 
 
100 
 
- 
 
- 
 
- 
 
- 
* standard deviation 
 
 
 7709315   38
4.1.3.  Sedative drug prescribing on admission  
 
Choice of sedative drug on admission 
As may be seen in Table 4.1.3 ‘Sedative drugs prescribed on admission’, the 
benzodiazepines clonazepam and lorazepam were the only sedating drugs that were 
prescribed.  6 of the 70 patients (8.5%) were given routine (only) sedation (clonazepam in 
5 cases and lorazepam in 1).  55 (78.6%) patients received PRN (only) sedation 
(clonazepam in 31 (44.3%) cases and lorazepam in 24 (34.3%).  Seven (10%) patients 
received both routine and PRN sedation, only 2 patients were not prescribed any sedation. 
 
Dose of sedative drug on admission 
Table 4.1.3 also shows that the patients who were prescribed clonazepam on a routine 
basis received a mean dosage of 3.5mg/d and a median dose of 3.25mg/d.  Of the 31 
(44.3%) patients who received clonazepam PRN (only), the mean dose was 5.2mg/d, the 
standard deviation was 5.1 and the dose range was 1mg to 12mg/d. The median dose of 
PRN clonazepam was 3.5mg/d.  The single patient who received lorazepam routinely was 
given a dose of 2mg/d.  Of the 24 (34.3%) prescriptions for lorazepam PRN (only), the 
average dose was 6.58mg/d, the standard deviation was 5.9 and the dose range was 
between 1 and 20mg/d.  The median PRN dose for lorazepam was 7mg/d. 
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Table 4.1.3.  Sedative drugs prescribed on admission  
Drug name/ 
N = number 
of patients 
on the drug 
Routinely
/ 
PRN  
Number 
of 
patients 
on the 
drug 
Per-
centage 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range 
of 
dose 
(mg) 
 
Median 
dose 
(mg/d) 
 
 
clonazepam 
N=43 
(61.4%) 
Routinely 
 
5 7.1 3.5 1.6 1.5-
5.5 
3.25 
PRN 
 
31 44.3 5.2 5.1 1-12 3.5 
Routinely 
and PRN 
7 10 - - - - 
 
lorazepam 
N=25 
(35.7%) 
Routinely 
 
1 1.4 2 - - - 
PRN 
 
24 34.3 6.5 5.97 1-20 7 
Routinely 
and PRN 
0 0 - - - - 
No sedative drug used 
N=2 (1.8%) 
2 1.8 - - - - 
 
Total N=70 
 
70 
 
100 
 
- 
 
- 
 
- 
 
- 
* standard deviation 
 
 
4.1.4 . Other psychotropic drugs prescribed on admission 
 
Sodium valproate (as Epilim CR©) was prescribed routinely to 7 (10%) patients at a mean 
dose of 1 314mg/d, with a standard deviation of 429.8, a range from 800mg/d to 1600mg/d 
and a median dose of 1200mg/d 
 
 
 7709315   40
4.2.  Prescribing at 14 days after admission 
 
4.2.1.  Antipsychotic drug prescribing at 14 days after admission 
 
Both first- and multiple-episode patient numbers combined 
From Table 4.2.1.1 ‘Antipsychotic drug prescribing at 14 days after admission (first- and 
multiple- episode patient numbers combined)’ it will be noted that at 14 days, there were 
37 (52.8%) prescriptions for FGAs (34 i.e. 48.6%) for haloperidol and 1 each for 
chlorpromazine, trifluoperazine and flupentixol.  The table also shows that there were 29 
(41.4%) prescriptions for SGAs, (25 i.e. 35.7%) for risperidone, 2 for clozapine and 2 for 
olanzapine).  Three prescriptions were for depot antipsychotic monotherapy, however, 
combination oral and depot antipsychotic drugs were prescribed for 9 (12.8%) patients.  
Only 1 patient did not receive any antipsychotic therapy.   
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Table 4.2.1.1.  Antipsychotic drug prescribing at fourteen days after admission 
(first- and multiple- episode patient numbers combined) 
 
Drug class/route,  
N = number of 
patients on  drug 
Drug name Mono- / poly- 
therapy 
Number of 
patients on the 
drug 
Percentage 
 
 
 
 
 
FGA (oral)  
N=37 (52.8%) 
 
 
haloperidol 
N=34 (48.6%) 
monotherapy 
 
26 37.1 
with prn 
clothiapine 
1 1.4 
with depot  
flupentixol*  
4 5.6 
with depot 
zuclopenthixol** 
3 4.2 
flupentixol (oral) 
 
monotherapy 1 1.4 
chlorpromazine monotherapy 
 
1 1.4 
trifluoperazine with depot 
zuclopenthixol** 
1 1.4 
 
 
 
 
SGA (oral) 
N=29 (41.4%) 
 
 
risperidone 
N=25 (35.7%) 
monotherapy 
 
23 32.8 
with PRN 
clothiapine 
1 1.4 
 
 
with depot 
flupentixol* 
1 1.4 
 
clozapine 
monotherapy 
 
1 1.4 
with PRN 
clothiapine 
1 1.4 
olanzapine monotherapy 2 
 
2.8 
 
FGA depot only 
N=3 (4.3%) 
flupentixol  Monotherapy – 
see * for 
combinations 
2 
 
2.8 
zuclopenthixol Monotherapy – 
see ** for  combos 
1 
 
1.4 
No antipsychotic N=1 (1.4%) 
 
1 1.4 
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Antipsychotic prescribing for the 12 first-episode patients at 14 days after 
admission 
 
Choice of antipsychotic drug for first-episode patients at 14 days after admission 
Table 4.2.1.2 ‘Antipsychotic drug prescribing at fourteen days after admission (first 
episode patients only’ shows that all 12 of the patients who presented with first-episode 
schizophrenia received antipsychotic medication to be taken routinely by mouth 
(haloperidol was prescribed for 8 patients, risperidone for 3 and olanzapine for 1).  
 
Dose of antipsychotic drug for first-episode patients at 14 days after admission 
The average dose of haloperidol prescribed for patients with first-episode schizophrenia 
was 6.5mg/d, the standard deviation was 2.6, the lowest dose in the range being 2.5mg/d 
and the highest 10mg/d.  The median dose of haloperidol monotherapy was 5mg/d.  The 3 
patients who were prescribed risperidone received doses of 3mg/d, 6mg/d and 4mg/d 
respectively.  
 
Table 4.2.1.2.  Antipsychotic drug prescribing at 14 days after admission – first 
episode patients only 
Drug 
class/  
N = 
number 
of 
patients 
on the 
drug 
Drug name Number 
of 
patients 
on the 
drug 
% of 
first 
episode 
patients 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range 
of dose 
 
Median 
dose 
(mg/d) 
FGA 
(oral)  
N=8 
haloperidol 
mono-
therapy 
8 66 6.5 2.6 2.5-10 
 
5 
 
SGA 
(oral) 
N=4  
risperidone 
mono-
therapy 
3 25 - - - - 
olanzapine 
mono-
therapy 
1 8.3 - - - - 
 
Totals N=12 
 
12 
 
100 
 
- 
 
- 
 
- 
 
- 
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Prescribing for the 58 multiple-episode patients at 14 after admission 
 
Choice of antipsychotic drug for multiple-episode patients 
Table 4.2.1.3 ‘Antipsychotic drug prescribing at 14 days after admission for multiple-
episode patients’ demonstrates that 19 (32.8%) of the 58 patients with multiple-episode 
schizophrenia received haloperidol antipsychotic monotherapy and 22 (37.9%) further 
patients were prescribed risperidone antipsychotic monotherapy.  Other oral antipsychotic 
monotherapy included flupentixol, chlorpromazine, trifluoperazine, clozapine and 
olanzapine; depot antipsychotic monotherapy included flupentixol and zuclopenthixol; 
various antipsychotic polypharmacy may be noted from the table.  One patient did not 
receive any oral antipsychotic medication at this time. 
 
At 2 weeks after admission, 2 patients received depot antipsychotic monotherapy – 1 was 
prescribed flupentixol and the other zuclopenthixol.  Combination depot and oral 
antipsychotic polypharmacy was given to 6 patients, which included oral haloperidol with 
flupentixol depot (4  patients), oral haloperidol with zuclopenthixol depot (t3 patients), oral 
trifluoperazine with zuclopenthixol (1 patient) and risperidone with flupentixol depot (1 
patient). 
 
Dose of antipsychotic drug for multiple-episode patients 
Table 4.2.1.3 also shows the average dose of haloperidol to be 5.1mg/d, with a standard 
deviation of 1.5, a dose range of 2.5mg/d to 10mg/ and a median dose of 5mg/d. The 
average dose of risperidone was 3.4mg/d, with a standard deviation of 1.4, a dose range 
of 1mg/d to 6mg/d and a median dose of 3.5mg/d.  The remaining drugs and dosages for 
oral antipsychotic monotherapy were: flupentixol of 1mg/d, chlorpromazine of 400mg/d, 
clozapine of 200mg/d and two prescriptions for olanzapine of 10mg and 20mg respectively 
 
The average dosage of flupentixol depot was calculated to be 7.1mg per week and for 
zuclopenthixol depot it was 57.5mg per week.  The lowest individual dose of flupentixol 
depot was 5mg per week and the highest was 10mg/wk.  The lowest individual dose of 
zuclopenthixol was 37.5mg per week and the highest was 100mg per week.   
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Table 4.2.1.3.  Antipsychotic drug prescribing at 14 days after admission – multiple-
episode patients receiving haloperidol, risperidone and olanzapine 
Drug 
class/  
N = 
number 
of 
patients 
on the 
drug 
Drug name Number 
of 
patients 
on the 
drug 
Per-
centage  
Mean 
dose 
SD* of 
dose 
Range 
of dose 
 
Median 
dose 
(mg/d) 
FGA 
(oral)  
N=19 
(27.1%) 
haloperidol 
mono-
therapy 
19 32.8 5.1 1.5 2.5-10 5 
SGA 
(oral) 
N=23  
(32.8%) 
risperidone 
mono-
therapy 
22 37.9 3.4 1.4 1-6 3.5 
olanzapine 
mono-
therapy 
1 1.7 - - - - 
All other antipsychotic 
treatment – both oral 
and depot forms 
15 25.8 - - - - 
No antipsychotic 
treatment – neither oral 
nor depot form 
1 1.7 - - - - 
 
Totals N=58 
 
58 
 
100 
 
- 
 
- 
 
- 
 
- 
* standard deviation 
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4.2.2.  Anticholinergic drug prescribing at 14 days after admission (first- and 
multiple- episode patient numbers combined) 
 
Choice of anticholinergic drug at 14 days after admission 
Table 4.4.2.  ‘Anticholinergic drug prescribing at 14 days after admission (first- and 
multiple- episode patient numbers combined) gives details of anticholinergic use at this 
time.  At 14 days after admission, no anticholinergic medication was prescribed for any 
patient with first-episode illness – neither routinely nor PRN.  Ten (14.2%) of the full 
complement of 70 patients in the study were prescribed anticholinergic medication on a 
routine basis at this time (9 patients received orphenadrine and 1 was given biperiden).  
With regard to the antipsychotic prescribing associated with the use of anticholinergic 
drugs, of these 10 patients, 8 were prescribed antipsychotic medication by mouth only, 1 
was receiving antipsychotic treatment by both oral and depot routes and 1 patient was 
receiving no antipsychotic medication at all.  There were no prescriptions for 
anticholinergic drugs to be given PRN.   
 
 
Dose of anticholinergic drug at 14 days after admission 
Both the mean and median doses for orphenadrine were 100mg/d with a standard 
deviation of 35.3 and a dose range of 50 to 150mg/d, while the dose of biperiden was 
6mg/d. 
 
Table 4.2.2.  Anticholinergic drug prescribing at 14 days after admission (first- and 
multiple- episode patient numbers combined) 
Drug name Number 
of 
patients 
on the 
drug 
Per-
centage 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range of 
dose 
 
Median 
dose 
(mg/d) 
orphenadrine 
 
9 12.8 100 35.3 50-100 100 
biperiden 
 
1 1.4 6 - - - 
No anti-
cholinergic  
60 85.7 - - - - 
 
Totals N=70 
 
70 
 
100 
 
- 
 
- 
 
- 
 
- 
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4.2.3.  Sedative drug prescribing at 14 days after admission (first- and multiple- 
episode patient numbers combined) 
 
Choice of sedative drug at 14 days after admission 
As will be noted from Table 4.2.3 ‘Sedative drug prescribing at 14 days after admission 
(first- and multiple- episode patient numbers combined)’, 6 (8.5%) patients were 
prescribed sedation on a routine basis only (5 patients received clonazepam and 1 
lorazepam).  Forty-eight patients (68.5%) were prescribed PRN sedation only (32 i.e. 
45.7% received clonazepam and 16 i.e. 22.8% were prescribed lorazepam).  Both routine 
and PRN sedation were given to 7 (10%) patients while a further 7 patients (10%) were 
not prescribed any sedation.  
 
Dose of sedative drug at 14 days after admission 
Table 4.2.3 also shows that the average dose of clonazepam prescribed routinely (only) 
was 5.2mg/d, with a standard deviation of 3.9 and a range of 1mg/d to 12mg/d.  The 
median dose was found to be 5mg/d. The dose for the patient who received lorazepam 
routinely was 6mg/d.  The average dose of clonazepam PRN (only) was 5.1mg/d, the 
standard deviation was 6.7, a range of 1mg/d to 24mg/d and a median dose of 4.5mg/d.  
The average dose of lorazepam PRN (only) was 5.9mg/d, with a standard deviation of 6.8, 
a range of 1mg/d to 20mg/d and a median dose of 7mg/d.   
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Table 4.2.3.  Sedative drug prescribing at 14 days after admission (first- and 
multiple- episode patient numbers combined) 
Drug name/ 
N = number 
of patients 
on the drug 
Routinely
/ 
PRN  
Number 
of 
patients 
on the 
drug 
Per-
centage 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range 
of 
dose 
(mg) 
Median 
dose 
(mg/d) 
 
 
clonazepam 
alone N=43 
(61.4%) 
Routinely 
 
5 7.1 5.2 3.9 1-12 5 
PRN 
 
32 45.7 5.1 6.7 1-12 4.5 
Routinely 
and PRN 
6 8.6 - - - - 
 
lorazepam 
alone 
N=18 
(25.7%) 
Routinely 
 
1 1.4 3 - - - 
PRN 
 
16 22.8 5.9 6.8 1-20 7 
Routinely 
and PRN 
1 1.4 - - - - 
clonazepam routinely 
with lorazepam PRN 
1 1.4 - - - - 
lorazepam routinely with 
clonazepam PRN 
1 1.4 - - - - 
No sedative drug used 
N=7 (10%) 
7 10 - - - - 
* standard deviation 
 
 
4.2.4.  Other psychotropic drugs prescribed at 14 days after admission 
 
Sodium valproate  
Sodium valproate (as Epilim CR) was prescribed routinely to 14 patients (20%) (2 of whom 
were first-episode patients).  13 (18.5%) of these were also receiving an antipsychotic 
drug for oral administration and one was prescribed a depot.  Sodium valproate was 
prescribed at a mean dose of 1200mg/d with a standard deviation of 389.2, a range of 
600mg/d to 1600mg/d and a median dose of 1200mg/d. 
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Fluoxetine 
At 14 days following admission, fluoxetine was administered to 2 patients at dosages of 
20mg/d and 40mg/d.  Neither of these patients received sodium valproate.  
 
Lithium carbonate 
1 patient received lithium carbonate at a dosage of 400mg/d.  This patient did not receive 
sodium valproate or an antidepressant.  
 
 
4.3.  Prescribing on hospital discharge – first- and multiple- 
episode patient numbers combined 
 
4.3.1.  Antipsychotic drug prescribing on hospital discharge  
 
Choice of antipsychotic drug on discharge 
As will be noted from Table 4.3.1.1 ‘Antipsychotic drug prescribing on hospital discharge’ 
69 (98.5%) patients received routine antipsychotic medication to take home when 
discharged from the hospital.  FGA antipsychotic monotherapy to be taken routinely by 
mouth was given to 6 (8.6%) patients (5 received haloperidol and 1 chlorpromazine); no 
PRN FGAs were prescribed.  SGA antipsychotic monotherapy to be taken routinely by 
mouth was prescribed for 31 (44.3%) patients, which included 21 (30%) prescriptions for 
risperidone, 2 for amisulpride, 2 for olanzapine and 6 (8.6%) for clozapine.   
 
Depot (only) antipsychotic medication was prescribed for 5 (7.1%) patients (2 received 
flupentixol and 3 zuclopenthixol).  Only 1 patient was not given antipsychotic medication 
upon discharge. 
 
Antipsychotic polypharmacy was prescribed for 27 (38.5%) patients upon hospital 
discharge. This combination pharmacotherapy included: 2 orally administered drugs for 3 
patients (clozapine with amisulpride for 1 patient and clozapine with risperidone for 1 
patient) and an orally administered antipsychotic with a depot to 24 (34.3%) patients (this 
comprised flupentixol with haloperidol, risperidone or clozapine in 15 (21.4%) patients; and 
zuclopenthixol with the same drugs in 9 (12.8%) patients).  No PRN SGAs were 
prescribed. 
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Table 4.3.1.1  Antipsychotic drug prescribing on hospital discharge  
 
Class/route  
N = number 
of patients 
on drug 
Drug name Mono- / poly- 
pharmacotherapy 
Number of 
patients on drug 
Percentage 
 
 
FGA (oral)   
N=18 
(25.7%) 
haloperidol  
N=17 
(24.3%) 
monotherapy 5 
 
7.1 
with depot  
flupentixol 
8 11.4 
with depot 
zuclopenthixol 
4 5.7 
chlorpromazine monotherapy 1  
 
1.4 
 
 
 
 
 
 
 
 
SGA (oral)  
N=46  
(65.7%) 
 
 
risperidone 
N=31 
(44.3%) 
monotherapy 21 
 
30 
with depot  
flupentixol 
6 8.6 
with depot 
zuclopenthixol 
4 5.7 
amisulpride monotherapy 2 
 
2.8 
olanzapine monotherapy 2 
 
2.8 
 
 
 
 
clozapine 
N=11 
(15.7%) 
monotherapy 6 
 
8.6 
with depot  
flupentixol 
1 1.4 
with depot 
zuclopenthixol 
1 1.4 
with amisulpride 1 
 
1.4 
with risperidone 2 
 
2.8 
FGA depot 
only 
N=5 
(7.1%) 
flupentixol  monotherapy 2 
 
2.8 
zuclopenthixol monotherapy 3 
 
4.2 
No antipsychotic treatment 
N=1 
1 1.4 
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Antipsychotic drug dose on hospital discharge 
As will be noted from Table 4.3.1.2 ‘Dosage parameters of the two most frequently 
prescribed antipsychotic drugs on discharge’, the average dose of haloperidol for the 5 
(7.1%) patients who received the drug upon hospital discharge was 5.1mg/d, the standard 
deviation was 1.6 and the range was from 2.5mg/d to 7.5mg/d. The median dose was 
5mg/d.  For the 21 (30%) patients who were prescribed risperidone, the average dose was 
4.6mg/d, the standard deviation 1.4 and the range was between 1mg/d and 6mg/d.  The 
median dose was 4mg/d. 
 
The average dose of flupentixol depot received by the 17 (42.3%) patients upon discharge 
was 9.2mg/wk with a range from 5mg/wk to 20mg/wk.  For zuclopenthixol depot the 
average dose was 53.4mg/wk with a dose range between 37.5mg/wk and 100mg/wk. 
 
 
Table 4.3.1.2  Dosage parameters of the two most frequently prescribed 
antipsychotic drugs on discharge  
Drug 
name 
mono- 
poly- 
therapy 
Number 
of 
patients 
on drug 
Per-
centage 
Average 
dose 
(mg/d) 
SD*  
of 
dose 
Range 
of dose 
(mg) 
 
Median 
dose 
(mg/d) 
haloperidol mono- 
therapy 
5 7.1 5.1 1.6 2.5-7.5 5 
risperidone mono-
therapy 
21 30 4.6 1.4 1-6 4 
* Standard deviation 
 
 
4.3.2.  Anticholinergic drug prescribing on hospital discharge  
 
 Choice of anticholinergic drug on hospital discharge 
As is shown in Table 4.3.2 ‘Anticholinergic drug prescribing on hospital discharge’, upon 
hospital discharge there were 20 (28.5%) patients who received anticholinergic medication 
to be taken routinely (17 for orphenadrine and 3 for biperiden).  No prescriptions for PRN 
anticholinergic drugs were noted. 
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Dose of anticholinergic drug on hospital discharge 
Table 4.3.2 also shows that the average dose of routinely administered orphenadrine was 
111.7mg/d, the standard deviation was 28.1, a dose range from 50mg/d to 150mg/d and a 
median dose of 100mg/d.  For biperiden the average dose was 4.3, the standard deviation 
was 1.1, the dose range was from 4mg/d to 6mg/d and a median dose of 6mg/d. 
 
 
Table 4.3.2  Anticholinergic drug prescribing on hospital discharge 
Drug name  Number 
of 
patients 
on drug 
Per-
centage 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range of 
dose 
 
Median 
dose 
(mg/d) 
orphenadrine 
 
17 24.3 111.7 28.1 50-150 
 
100 
biperiden 
 
3 4.3 5.3 1.1 4-6 6 
No anti-
cholinergic 
drug 
50 71.4 - - - - 
 
Totals 
 
70 
 
100 
- - - - 
* standard deviation 
 
 
 
4.3.3.  Sedative drug prescribing on hospital discharge 
 
Choice of sedative drug on hospital discharge 
Upon hospital discharge there were 16 (22.8%) patients who received prescriptions for 
benzodiazepines to be taken routinely (11 i.e. 15.7% for clonazepam and 5 i.e. 7.1% for 
lorazepam).  Only 1 prescription limited the duration of the clonazepam to be taken 
routinely – this was for 14 days following hospital discharge.  5 (7.1%) prescriptions for 
PRN benzodiazepines (4 for clonazepam and 1 for lorazepam) were noted.  No 
benzodiazepine sedatives were given to 49 (70%) patients and none received both routine 
and PRN sedation.  
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Dose of sedative drug dose on hospital discharge 
The average dose of the routinely administered clonazepam was 1.1mg/d, with a dose 
range from 0.5mg/d to 2mg/d and a median dose of 1mg/d.  The average dose of routinely 
administered lorazepam was 1.9mg/d with a dose range between 1mg/d and 2.5mg/d and 
a median dose of 2mg/d.  The average dose of PRN clonazepam prescribed for four 
patients was 5.9mg/d and the median dose was 1.5mg/d. The maximum dose of PRN 
clonazepam (including routine prescribing) was 24mg/d and for lorazepam the figure was 
2.5mg/d.   
 
 
Table 4.3.3.  Sedative prescribing on hospital discharge  
Drug name/ 
N = number 
of patients 
on drug 
Routinely 
/ 
PRN  
Number 
of 
patients 
on drug 
Per-
centage 
Mean 
dose 
(mg/d) 
SD* of 
dose 
Range 
of dose 
(mg) 
 
Median 
dose 
(mg/d) 
 
clonazepam  
N=43 
(61.4%) 
Routinely 
 
11 15.7 1.1 0.59 0.5-2 
 
1.0 
PRN 
 
4 5.7 5.9 10.1 1-24 
 
1.5 
 
lorazepam  
N=18 
(25.7%) 
Routinely 
 
5 7.1 1.9 0.54 1-2.5 2 
PRN 
 
1 1.4 - - - - 
No sedative drug used 
N=7 (10%) 
49 70 - - - - 
 
Totals 
 
70 
 
100 
 
- 
 
- 
- - 
* standard deviation 
 
 
4.3.4.  Other psychotropic drugs prescribing on hospital discharge 
 
Sodium valproate was prescribed for routine use by 20 (28.5%) patients and the 
antipsychotic drugs taken with this varied.  6 patients received haloperidol in addition to 
sodium valproate (additionally, 2 of these patients received flupentixol depot and 2 
zuclopenthixol depot).  7 (10%)  patients received risperidone in addition to sodium 
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valproate (with 2 of these also receiving flupentixol depot and 2 zuclopenthixol depot).  A 
further 5 (7.1%) prescriptions were noted with combinations of sodium valproate and 
clozapine, 1 for amisulpride and sodium valproate and the remaining patient was given 
zuclopenthixol depot but no oral antipsychotic.    
 
The average dose of sodium valproate was 1120mg/d, with a standard deviation of 375 
and a range from 400mg/d to 2000mg/d.  The median dose of sodium valproate was 
1200mg/d. 
 
Two of the 70 patients were prescribed fluoxetine, both at a dosage of 20mg/d (the same 2 
patients who had received the drug at 14 days following admission.  The same patient who 
was prescribed lithium carbonate previously continued to receive this at the same dosage 
of 400mg/d.  2 other patients received citalopram at a dosage of 10mg/d, 1 of whom was 
also given sodium valproate.   
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Chapter 5 – Discussion 
 
The results of the data analysis are now compared with the clinical practice guidelines 
used during this study, in order to assess to what extent there is agreement.  The degree 
of concordance will determine whether or not further research is warranted to ensure that 
the prescribing for patients with schizophrenia is characterised as evidence-based, 
efficacious and safe, with less variance and greater fidelity to guidelines that are generally 
and universally accepted as a standard of good practice. 
 
 
5.1.  The choice of antipsychotic drugs in the study 
 
5.1.1  Oral antipsychotic drug choice 
 
As has already been mentioned, the majority of patients in this study were referred by 
external sources and the prescribing on admission may not be an accurate reflection of 
the pharmacotherapeutic practices of the clinical staff at the hospital.  Despite this caveat, 
the very high frequency of the use of the FGA drug haloperidol by 56 (80%) patients at a 
dose of 5mg/d by 48 (68.6%) of these, suggests that ‘haloperidol 5mg/d’ is the standard 
prescribing practice for a patient with predominantly psychotic symptoms to the hospital.   
 
A total of 58 (82.5%) patients received FGAs, whereas 11 (15.7%) were prescribed SGAs 
(10 of which were for risperidone). The preponderance of the use of FGAs over SGAs is 
not in keeping with the recommendations given in the clinical practice guidelines that were 
examined for the purpose of comparison in the study 
 
Of note is that ‘rapid neuroleptisation’ was not prescribed for any patient on admission, 
which is consistent with the NICEGs but may reflect the fact that patients are generally 
referred from other centres where the patients’ initial presentation may have included a 
greater degree of behavioural disturbance.   
 
After 14 days in hospital, more definitive treatment is likely to have been commenced and 
the number of prescriptions for oral FGAs at this data collection point decreased to 37 
(52.8%), including 34 (48.6%) for haloperidol.  The number of prescriptions for oral SGAs 
rose to 30 (42.8%), including 25 (35.7%) for risperidone - these figures are for both first- 
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and multiple-episode patients combined – and are more consistent with the guidelines 
which recommend SGAs as the drug class of first choice for both the emergency- and the 
non-emergency- management of the acute phase of schizophrenia.   
 
FGAs are suggested as an option by the NICEGs if the patient and physician choose 
these drugs over SGAs after considering the advantages and disadvantages of both 
groups.  The RSAGs state that FGAs may be used where SGAs are unavailable in South 
Africa – which is not the case in this study according to the list of available drugs in 
Appendix D.  The ANZGs specifically advise against the use of FGAs.  It will be 
remembered that switching from FGAs to SGAs is recommended by the ANZGs and 
ECGS if the patient has relapsed while on FGAs or if there are efficacy or tolerability 
problems and are possible reasons (inter alia) for greater emphasis on the prescribing of 
SGAs. 
 
A high use of oral SGAs was not found when the prescriptions for only first-episode 
patients at fourteen days of hospital treatment were analysed: 8 of the 12 patients 
received haloperidol and 4 an oral SGA.  Given the greater susceptibility to adverse 
effects of FGAs and the importance of medication compliance, SGAs are considered the 
drugs of first choice for first-episode schizophrenia by the ECGs, CCPGs, ANZGs and 
RSAGs.   
 
By the time of hospital discharge, the orally administered antipsychotic prescribing profile 
showed a further reduction in the use of FGAs to 18 (24.7%) and another increase in the 
use of SGAs to 46 (65.7%).   
 
The decline in oral FGA prescribing from 58 (82.8%) at the time of admission, to 27 
(52.8%) after 14 days, to 18 (24.7%) may therefore be considered a positive trend 
according to the guidelines studied, as may the increase in oral SGA use from 11 (15.7%) 
newly admitted patients, to 29 (41.4%) after 14 days, to 46 (65.7%) by the time of 
discharge.   
 
However, there was a concomitant increase in the use of antipsychotic polypharmacy 
which is discouraged by all the guidelines studied.  The prescribing of oral FGA with depot 
FGA was noted twice on admission, this increased to 8 (11.4%) after 14 days, and to 12 
(17.1%) patients on discharge.  Similarly, the prescribing of oral SGA and depot FGA 
increased from nil on admission, to one after 14 days to 11 (15.7%) on discharge.  There 
were no instructions on any of the prescriptions examined for a tapering or discontinuation 
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of the oral antipsychotic.  It is possible that such a request was made in the discharge 
letter to the out-patient psychiatrist, but as the clinical notes were not examined it is not 
known if this was the case. 
 
 
5.1.2.  Depot antipsychotic drug choice and antipsychotic polypharmacy 
 
Although the increase in polypharmacy may be viewed unfavourably, the greater use of 
depot antipsychotic (albeit with FGA preparations) is more in accord with the guidelines 
studied.  Whereas on admission to the hospital, only 2 (2.8%) patients were receiving 
depot antipsychotic drugs; at 14 days, this figure had increased to twelve (17.1%); and 
upon hospital discharge, there were 29 (41.3%) prescriptions for depot preparations.  It 
has been noted that because adherence to medication is a significant factor in the relapse 
of patients with schizophrenia, use of the depot form of an antipsychotic is encouraged.  It 
is recommended by ECGs, ANZGs, NICEGs, APAGs and RSAGs for patients who prefer 
it and for patients who may not be relied upon to take medication as prescribed.   
 
Depot monotherapy was not noted on the prescriptions of newly admitted patients but 3 
(4.3%) patients received this after 14 days, and 5 patients on discharge.  It is likely that the 
2 patients who received both oral and depot FGAs on admission had not presented for the 
first time and were patients with multiple-episode schizophrenia. 
 
As has been noted in the review of the literature preceding this study, antipsychotic 
polypharmacy is discouraged by many authors on the grounds that there is no evidence-
base for the practice and is seen to be counter-productive because it may result in more 
severe adverse reactions and thereby may reduce patients’ compliance with medication.  
All the guidelines consulted recommend monotherapy particularly for the stable phase of 
schizophrenia – the increase in the use of antipsychotic polypharmacy noted on hospital 
discharge is not concordant with this principle, although the small increase in depot 
antipsychotic monotherapy may be encouraging.  
 
 
5.2.  Antipsychotic drug dosage and titration 
Given that the use of antipsychotic polypharmacy bedevils attempts to compare the dose 
of an antipsychotic used in routine practice with the monotherapeutic doses found in 
clinical practice guidelines, it was necessary to make use of small sample sizes at some 
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data collection points.  Only the dosages of haloperidol and risperidone lent themselves to 
any useful analysis.  
 
 
5.2.1.  Dosages of haloperidol monotherapy 
 
The average dose of haloperidol antipsychotic monotherapy given to 51 (72.8%) newly 
admitted patients was 4.8mg/d and the median dose was 5mg/d.  For 8 (11.4%) first-
episode patients after two weeks in hospital, the average dose was 6.5mg/d and the 
median dose was 5mg/d.  For the 19 (32.8%) multiple-episode patients after two weeks in 
hospital, the mean dose was it was 5.1mg/d and the median dose was 5mg/d.  For the 5 
(7.1%) patients on discharge the mean dose was 5.1mg/d and the median dose was 
5mg/d.   
 
The mean and median doses were nearly identical at the sampling times - apart from the 8 
first-episode patients who received haloperidol two weeks after admission.  At that point, 
the mean dose of 6.5mg/d was higher than that prescribed for multiple-episode patients, 
however, the median dose was the same (5mg/d).  The value of 6.5mg/d lies in the range 
of 5mg/d – 10mg/d which the guidelines recommend as an average target dose range for 
first-episode patients, however, it is difficult to draw a comparison with the guidelines 
because the number of first-episode patients in the study is so small.     
 
 
5.2.2  Dosages of risperidone monotherapy 
 
On admission to hospital, the mean and median dosages of risperidone were the same 
(4mg/d).  
 
Three of the first-episode patients received risperidone monotherapy at 14 days after 
admission at dosages of 3mg/d, 4mg/d and 6mg/d.  Although the patient numbers are 
small, the starting dosages are in excess of the guidelines for risperidone viz. 1mg/d - 
2mg/d (ECGs), 0.5mg/d - 1mg/d (CCPGs) and 2mg/d (ANZGs).   
 
Twenty-two (37.9%) multiple-episode patients received risperidone monotherapy at 14 
days after admission at an average dose of 3.4mg/d, with a standard deviation of 1.4, a 
dose range of 1mg/d to 6mg/d and a median dose of 3.5mg/d.  The mean and median 
doses were again almost identical, and these values correspond to the target daily doses 
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recommended by the CCPGs of 2mg/d - 6mg/d and are lower than the 6mg/d suggested 
by the ECGs.  These conclusions are acceptable given that only one of the patients 
received a depot antipsychotic.   
 
Upon discharge, the 21 (30%) patients who were prescribed risperidone received a dose 
of 4.6mg/d, with a standard deviation of 1.4, a dose range of 1mg/d to 6mg/d and a 
median dose of 4mg/d.  The median dose of risperidone at this point differed by only  
0.6mg/d which may be therapeutically relevant, however, both dosages are in keeping with 
the guidelines mentioned above.  
 
 
5.3  Choice of  Anticholinergic drugs used in the study 
It has been noted that on admission to hospital, anticholinergic drugs was prescribed for 
routine use by 10 (14.2%) patients; there were no PRN prescriptions for these drugs.  The 
clinical practice guideline recommendations for the pharmacological management of 
extrapyramidal side-effects do not include the use of anticholinergic agents, and the 
prophylactic use of anticholinergic drugs is not recommended by the ECGs and the 
CCPGs.  Although their use is permitted by the APAGs, these guidelines recommend 
using SGAs (except with high doses of risperidone) if there is a history of sensitivity to 
extra-pyramidal side-effects (other than tardive dyskinesia).  Without the clinical history of 
the individual patients who received anticholinergic drugs for routine administration, it is 
not possible to determine if the agents were used in a way that is in keeping with guideline 
recommendations. 
 
For extrapyramidal side-effects (other than akathisia and tardive dyskinesia), switching 
from an FGA to an SGA is advised and if the symptoms are severe, clozapine is 
suggested (ECGs and APAGs).  Other options include dose-reduction or switching from 
high- to low-potency FGAs.   
 
At 14 days following hospital admission, the same 10 (14.3%) patients who had been 
prescribed anticholinergic drugs continued to receive them. This was not in response to 
the commencement of depot antipsychotic drugs because of the 10 patients only 1 had 
been prescribed a depot since admission and the other patient was on no antipsychotic 
medication at all.   
 
Of these 10 patients, 4 were not prescribed an FGA by mouth or via depot injection, 3 
were given the SGA risperidone by mouth and the remaining patient received clozapine.  
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The CCPGs state that ‘anticholinergic medication is not usually recommended with the 
use of SGAs’ - rather the reverse - the APAGs and RSAGs suggest prescribing these 
drugs if a patient develops extrapyramidal side-effects on an FGA.  It is therefore not clear 
why the 3 patients who received risperidone were prescribed an anticholinergic drug for 
routine administration, nor is it evident why a patient who was not receiving antipsychotic 
treatment should be receiving an anticholinergic drug routinely.  It is possible that the 
patient who received both clozapine and biperiden at all three data collection points was 
given the anticholinergic drug for clozapine-induced hyper-salivation or excessive 
sweating occasioned by the use of the drug, however, the potential of a pharmacodynamic 
interaction exists with this combination of drugs because clozapine has marked intrinsic 
anticholinergic properties.   
 
On discharge, more than a quarter of the prescriptions (20 patients i.e. 28.6%) included 
anticholinergic drugs to be taken routinely.  Of these, 6 were to be taken with an orally 
administered antipsychotic only (1 prescription was for the FGA chlorpromazine and 5 for 
SGAs including 3 for risperidone, 1 for amisulpride and 1 for clozapine).  Three of the 
prescriptions for a routinely administered oral anticholinergic included a depot 
antipsychotic only, while the remaining 11 prescriptions for routine anticholinergic drug use 
included a combination of a depot and an oral antipsychotic drug (in each case the depot 
was an FGA but the oral medication differed in that there were 7 FGAs and four SGAs). 
 
It is noteworthy that 7 of the 10 patients who were prescribed routine anticholinergic drugs 
at 14 days after hospital admission, received the same drugs upon discharge, with no 
stipulation as to the intended duration of use.   
 
In summary, anticholinergic drugs were used increasingly over the three data collection 
points with more than a quarter of patients receiving them upon hospital discharge.  The 
use of anticholinergic drugs in the study is not consonant with the recommendations of the 
clinical practice guidelines that refer to them.  
 
 
5.4.  Anticholinergic drug dose and titration 
There was little guidance for the use of anticholinergic agents in the guidelines and 
comparisons could not be drawn. 
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5.5.  The choice of sedative drugs used in the study 
On admission to hospital, 6 (8.6%) patients were prescribed benzodiazepine sedatives to 
be taken routinely, all of whom remained on the medication for at least 14 days, and 3 of 
the 6 received sedatives upon discharge (1 patient received clonazepam and 2 
lorazepam).   
 
Benzodiazepines are recommended to manage acute agitation in the emergency situation 
(ANZGs and APAGs) as well as in non-emergency management while titrating the dose of 
the antipsychotic (CCPGs).  Midazolam and clonazepam are recommended by the ANZGs 
for the management of the combative patient.   
 
Benzodiazepine sedation may have been prescribed as an anticonvulsant.  Given that the 
patients’ clinical notes were not examined in this study, it is not possible to determine if the 
sedation was given for seizure control. 
  
A total of 16 (22.9%) patients were given benzodiazepine sedatives for routine use on 
discharge – only one prescription (for clonazepam) limited the number of tablets to be 
dispensed.  The long-term use of benzodiazepines is not supported by the guidelines 
studied. 
 
 
5.6.  Sedative drug dose and titration 
The mean and median dosages of routinely administered clonazepam and lorazepam 
were very similar from hospital admission to discharge, however, some of the mean and 
median dosages of medication given PRN differed considerably at two sampling points.  
These included the PRN prescribing of clonazepam on admission (where the mean dose 
exceeded the median dose by 1.7mg/d) and on discharge (where the mean dose was 
4.4mg/d higher than the median dose).  These differences demonstrate how calculating 
only the average dose of medication may not reflect the prescribing practice. 
 
Unfortunately, little mention is made in the guidelines with regard to the dosages of 
benzodiazepines, however, the use of lorazepam PRN as it was prescribed could have 
been toxic at a dose of 24mg/day.   
 
 
 7709315   61
5.7.  Other drugs - choice and dose 
 
5.7.1.  Sodium Valproate 
 
On admission to hospital there were 7 (10%) patients who received sodium valproate, at 
14 days into their hospital stay the number had risen to 14 (20%) and on discharge more 
than a quarter of patient - 20 in number (28.6%) - had been prescribed the drug.  The 
mean and median dosages of sodium valproate were either the same or very similar. 
 
The use of mood stabilisers is recommended by the ANZGs for severe depression and by 
APAGs and ECGs for aggression and violence.  The reason for the high number of 
prescriptions for sodium valproate found in this study is not clear.  It is possible that the 
drug was used as an adjunct to antipsychotic medication in patients with treatment-
resistant schizophrenia, given that 5 of the 10 patients who were given sodium valproate 
and clozapine on hospital discharge, but there is no clear evidence base for this practice.  
It was not limited to one prescriber, but to three consultant psychiatrists, and may be an 
idiosyncrasy of the Facility but this is speculation - the reason is unknown at this time. 
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Chapter 6 – Conclusions, Limitations and 
Recommendations 
 
6.1.  Conclusions 
Given that the clinical practice guidelines utilised in this study are based on evidence-
based practice and a consensus of experts, they were considered a satisfactory standard 
against which to compare the prescribing practices of psychiatrists treating schizophrenia 
at the Facility.  While the findings highlight concerns that have been identified by other 
studies, there are also encouraging trends towards less variance in prescribing.  Some of 
these points are now expanded upon. 
 
With regard to the prescribing of antipsychotic medication, as compared with the clinical 
practice guidelines consulted in the study there was an overuse of FGAs and an underuse 
of SGAs.  This was noted with reference to both oral and depot drugs despite the depot 
form of the SGA risperidone having being available throughout the three years over which 
the sample population was hospitalised.  It will be remembered that it is good practice for 
an oral SGA be followed by a depot SGA, not a depot FGA which was always the case in 
this study.  
 
Although the numbers were small, the antipsychotic prescribing at 14 days is a concern 
given that the use of FGAs predominated and the average doses were higher than both 
the multiple-episode patients and the recommendations made in the guidelines for first-
episode patients.  The use of depot antipsychotic drugs is a positive finding, however, it is 
compromised by the increase in antipsychotic polypharmacy - most often due to oral and 
depot co-prescribing.   
 
Routine anticholinergic drugs were given to the same 10 patients on admission as at 14 
days thereafter.  This is a practice that is not recommended by the guidelines consulted 
which suggest the use of an SGA if extrapyramidal side-effects are troublesome.  It was 
surprising that there was no evidence of PRN anticholinergic use instead of regular use.  It 
was also surprising that 4 patients who had been prescribed oral SGA monotherapy and 1 
who was not on any antipsychotic medication were also receiving an anticholinergic drug.  
The potential for a pharmacodynamic interaction that exists with clozapine – which was 
one of the SGA drugs prescribed with an anticholinergic drug – has been mentioned.   
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On hospital discharge, more than a quarter of patients were given anticholinergic agents to 
be taken routinely despite a lack of correlation with the use of oral or depot FGAs.  This 
may be viewed as irrational pharmacotherapy and is not supported by the relevant 
guidelines.  The use of benzodiazepine drugs was generally in keeping with the guideline 
recommendations in that they were prescribed PRN, however, the dose range of up to 
24mg/d of lorazepam was unacceptably high.  The reasons for 16 patients receiving 
ongoing routine benzodiazepine treatment is not clear from the prescriptions and is not 
recommended in the guidelines examined.   
 
The high frequency of prescribing of sodium valproate was an unexpected finding.  The 
use of the drug is recommended in the guidelines for aggression/violence and for severe 
depression, however, more than a quarter of all patients with schizophrenia received the 
drug on hospital discharge despite one of the exclusion criteria for patient selection was 
schizoaffective disorder.  It is not clear why sodium valproate was used so frequently, 
especially given that there is no evidence-base for the prescribing of the drug.   
 
While there are numerous other conclusions that may be reached from comparing the 
results of the data analysis of this study and comparing the parameters with those found in 
the clinical practice guidelines examined, a number of relevant points have been identified. 
 
 
6.2.  Limitations 
There are a number of limitations to this study including its retrospective design with 
convenience sampling which may have resulted in bias.   
 
The patients’ clinical files that provide details of symptoms and progress with treatment 
were not examined and some of the reasons for the variance in prescribing parameters 
could not be determined.  Examples of where this would be have been helpful include: to 
ascertain why sodium valproate was prescribed for so many patients; whether or not oral-
depot antipsychotic polypharmacy was to have been temporary or on-going; why 
benzodiazepine drugs were prescribed for routine use to a large number of patients on 
discharge and why anticholinergic agents were used with SGA antipsychotic monotherapy.  
These and other questions may be answered with the benefit of detailed clinical records. 
 
Another factor is the age of the guidelines used in this study.  This a source of concern 
given that they range from 1998 to 2009 – a span of eleven years - the oldest of the six 
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being the South African document.  The local guideline was written before the use of 
SGAs became commonplace, whereas the pharmacy at the hospital where the study was 
conducted is able to supply patients with not only oral SGAs, but also in depot form.   
 
 
6.3.  Recommendations 
By comparing the findings of this study with established standards of best practice, several  
concerns have been highlighted.  Given the limitations of this retrospective study of 
prescribing data exclusively, it is recommended that a prospective pilot study with the 
relevant clinical information in addition to the data from the prescriptions for psychotropic 
agents be undertaken to qualify and quantify with greater precision the extent of fidelity or 
the lack thereof to standards of international best practice in the pharmacotherapy of 
schizophrenia. 
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Appendix A 
 Diagnostic criteria for schizophrenia  
 
A.  Characteristic symptoms:  Two (or more) of the following, each present for a significant 
portion of time during a 1-month period (or less if successfully treated): 
(1)  delusions 
(2)  hallucinations 
(3)  disorganized speech (e.g. frequent derailment or incoherence) 
(4)  grossly disorganized or catatonic behaviour 
(5)  negative symptoms, i.e. affective flattening, alogia or avolition 
 
B.  Social/occupational dysfunction:  For a significant port of the time since the onset of the 
disturbance, one or more major areas of functioning such as work, interpersonal relations, 
or self-care are markedly below the level achieved prior to the onset (or when the onset is 
in childhood or adolescence, failure to achieve expected level of interpersonal, academic 
or occupational achievement).  
 
C.  Duration:  Continuous signs of the disturbance persist for at least 7 months.  This 6-
month period must include at least 1 month of symptoms (or less if successfully treated) 
that meet Criterion A (i.e. active-phase symptoms) and may include periods of prodromal 
or residual symptoms.  During these prodromal or residual periods, the signs of the 
disturbance may be manifested by only negative symptoms or two or more symptoms 
listed in Criterion A present in an attenuated form (e.g. odd beliefs, unusual perceptual 
experiences).  
 
D.  Schizoaffective and Mood Disorder exclusion:  Schizoaffective Disorder and Mood 
Disorder With Psychotic Features have been ruled out because either (1) no Major 
Depressive, Manic, or Mixed Episodes have occurred concurrently with the active-phase 
symptoms; or (2) if mood episodes have occurred during active-phase symptoms, their 
total duration has been brief relative to the duration of the active and residual periods. 
 
E.  Substance/general medical condition exclusion:  The disturbance is not due to the 
direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a 
general medical condition. 
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F.  Relationship to a Pervasive Developmental Disorder:  If there is a history of Autistic 
Disorder or another Pervasive Developmental Disorder, the additional diagnosis of 
Schizophrenia is made only if prominent delusions or hallucinations are also present for t 
least a month (or less if successfully treated).  
 
(source: American Psychiatric Association: Diagnostic and Statistical manual of Mental 
Disorders, 4th Ed.  Washington, DC, American Psychiatric Assoc. 1994) 
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Appendix B - Table 1 - Emergency (see glossary) pharmacotherapeutic management of the acutely psychotic patient 
(First choice is in bold) 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Emergency 
management: 
Choice of class of 
antipsychotic/ 
sedative 
 
SGAs/ 
Zuclopenthixol 
SGAs.  
Avoid FGAs. 
Benzodiazepines 
SGA 
SGA/FGA 
 
Avoid ‘rapid 
neuroleptisation’  
 
SGA/FGA 
with/without 
benzodiazepine 
 
Route of 
administration 
 
Oral, IMI 
(intramuscular 
injection) or 
rapidly-dissolving 
form of SGA 
If accepts give oral 
medication.  If 
refuses give IMI 
For further 
information see 
NICE guideline on 
the management of 
violence 
If patient accepts, 
give orally (rapidly 
dissolving forms) 
 
If refuses give via 
parenteral route 
 
Choice of drugs 
and dosages 
 
Olanzapine 2.5-
10mg (10mg is 
most frequently 
used) 
If non-combative: 
lorazepam 1-2mg 
or diazepam 5-
10mg. 
olanzapine 5-10mg 
or quetiapine 50-
100mg 
 
If combative: 
midazolam 5mg 
clonazepam 0.5-
2mg or 
olanzapine 
 If accepts orally: no 
choice of drug 
given  
 
If patient refuses 
oral medication:  
haloperidol/  
ziprasidone/ 
olanzapine – no 
dosages given 
 
Can use droperidol 
in extreme 
emergency 
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Appendix B - Table 2 - Acute phase pharmacotherapy (non-emergency) in first episode patient 
(First choice is in bold) 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Choice of class of 
antipsychotic/ 
sedative, dosages 
and titration 
SGA 
 
Starting dose 
(mg/day)  
haloperidol 2-5, 
olanzapine 5-10, 
quetiapine 50-100, 
risperidone 1-2, 
ziprasidone 40-80 
 
Average target 
dose (mg/day): 
haloperidol 5-10, 
olanzapine 10-15, 
quetiapine 300, 
risperidone 4, 
ziprasidone 80-120 
SGA 
Benzodiazepine 
 
Start with low dose 
of SGA (mg/day) 
risperidone 0.5-1.0, 
olanzapine 5-10, 
quetiapine 100.  
 
 Titrate at not less 
than weekly 
intervals to target 
dose of SGA 
(mg/day):  
risperidone 2-6, 
olanzapine 10-20, 
quetiapine 600 
 
Benzodiazepines to 
control agitation 
while antipsychotic 
dose is titrated. 
SGA as first and 
second line. 
 
Increase within 7 
days to initial target 
dose (mg/day)  
risperidone 2, 
olanzapine 10, 
quetiapine 300, 
amisulpride 400, 
aripiprazole 15 
 
Maintain for 3 
weeks.  If poor 
response, increase 
over next 4 weeks 
to maximum dose 
(mg/day) 
risperidone 4 
olanzapine 20 
quetiapine 600 
amisulpride 800 
aripiprazole 30 
SGA or FGA  
Choice of drug is 
made with relative 
potential of 
individual drugs to 
cause side-effects 
in the specific 
patient 
 
 
 
SGA 
In settings in South 
Africa where SGAs 
are not available, 
clinicians must rely 
on FGAs 
 
Use lower doses of 
antipsychotic drugs 
in first episode 
psychosis -  
(300g – 500g 
chlorpromazine 
equivalents) 
 
Give each drug trial 
a reasonable length 
of time before 
switching to another 
antipsychotic (4 to 6 
weeks) 
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Appendix B - Table 3 - Acute phase pharmacotherapy (non-emergency) in multiple episode patient 
(First choice is in bold) 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Choice of class of 
antipsychotic/ 
sedative, dosages, 
titration and 
duration of trial of 
drug 
SGA 
 
If the patient is 
acutely ill despite 
good compliance 
with FGA, switch to 
SGA. If the patient 
is non-compliant or 
denies illness 
persistently use 
depot.  
FGA depot is last 
resort. 
 
Starting dose 
(mg/day)  
haloperidol 2-5, 
olanzapine 5-10, 
quetiapine 50-100, 
risperidone 1-2, 
ziprasidone 40-80 
 
Average dose 
(mg/day)  
haloperidol 8-12 
olanzapine 15-20 
quetiapine 300-600 
risperidone 6 
ziprasidone 160 
 
Length of trial is 6-7 
weeks for drugs 
given above 
 
 
SGA  
 
Introductory range 
(total mg/day) 
risperidone 0.5-1 
olanzapine 5-10 
quetiapine 100 
 
Titrate up to initial 
target dosage in 1-2 
weeks  
 
Usual target dose 
(total mg/day): 
risperidone 2-6 
olanzapine 10-20, 
quetiapine 600 
 
Maximum dose 
(total mg/day): 
risperidone 8 
olanzapine 20 
quetiapine 800 
 
Adequate trial of 4-
8 weeks on max 
tolerated dose in 
recommended 
range of 300mg 
chlorpromazine 
equivalents for 
FGAs and within 
approved dosage 
ranges for SGAs 
SGA 
 
If acutely ill despite 
good compliance 
with FGA, switch to 
SGA. If on FGA but 
efficacy or 
tolerability 
problems, switch to 
SGA. If side-effects 
with SGA, switch to 
FGA or another 
SGA. 
If treatment 
resistance switch to 
clozapine 
SGA or FGA  
Choice of drug is 
made with relative 
potential of 
individual drugs to 
cause side-effects 
in the specific 
patient 
 
Start with a dose at 
the lower end of the 
licensed range and 
titrate upward only 
within the range 
given in the British 
National Formulary 
 
Carry out a trial at 
optimum dosages 
for 4-6 weeks 
Selection is guided 
by patients’ 
previous 
experience with 
antipsychotics 
including efficacy, 
side-effects and 
preference for route 
of administration.  
SGAs are 
preferred, however, 
the debate over the 
relative advantages 
and disadvantages 
of FGAs and SGAs 
is acknowledged.  
Consider the 
patient’s history of 
dose needs and 
response, clinical 
condition and 
severity of 
symptoms. 
Titrate the dose as 
quickly as tolerated 
to target therapeutic 
dose, then raise 
dose/change drug 
after 2-4 weeks.  
Initial response may 
take 2-4 weeks, full 
response up to 6 
months.  FGA dose 
is optimal at 
extrapyramidal 
threshold 
SGA 
In settings in 
South Africa 
where SGAs are 
not available, 
clinicians must 
rely on FGAs 
 
Use a dose range 
of 300g – 1000g 
chlorpromazine 
equivalents – 
preferably less 
than 700g 
chlorpromazine 
equivalents 
 
Give each drug 
trial a reasonable 
length of time 
before switching 
to another 
antipsychotic (4 
to 6 weeks) 
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Appendix B - Table 4 - Stabilization phase pharmacotherapy 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Stabilization phase   Depression is a 
common problem in 
first episode 
patients and 
antidepressant 
medication may be 
required.  
Medications 
selected for short-
term control of 
agitated behaviour 
during the acute 
psychotic phase 
may not be optimal 
for efficacy and 
tolerability. 
The use of depot 
formulations is an 
evidence-based 
pharmacological 
intervention for 
reducing 
noncompliance with 
oral medication. 
  Controlled trials 
have provided 
relatively little 
guidance for 
medication 
treatment during 
this phase 
Drug holidays and 
intermittent 
treatment are not 
recommended  
 
Onset of depression 
after treatment of 
the acute psychotic 
episode is 
particularly 
important to treat 
 
Systematic reviews 
of adjunctive drugs 
to augment 
antipsychotic 
treatment (e.g. 
lithium, 
carbamazepine) do 
not show a 
statistically 
significant 
improvement – (see 
Leucht et al, 2002) 
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Appendix B - Table 5 - Stable phase pharmacotherapy 
  
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
 (2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Type of 
antipsychotic agent 
for first-line use 
SGA SGA   FGA or SGA  
Monotherapy vs. 
polypharmacy 
 
Monotherapy Monotherapy Monotherapy Monotherapy Monotherapy Monotherapy 
Anticholinergic 
prophylaxis for 
EPSE 
 
Not recommended Not recommended   Permitted  
Dose/ other  There is a high level 
of individual 
variability in the 
dose of 
antipsychotic 
required to achieve 
functional recovery 
with minimal side-
effects.   
 
   Longer term 
antipsychotic drug 
treatment than 
previously is 
recommended, 
especially if SGAs 
are used 
 
Dosages may be 
reduced to 300g – 
600g 
chlorpromazine 
equivalents 
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Appendix B - Table 6 - Pharmacotherapy in the event of inadequate response to treatment 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Inadequate 
response to 
treatment 
For persistent 
positive symptoms, 
if the inadequate 
response was: to 
FGA, switch to 
SGA; to SGA, 
switch to different 
SGA or raise dose 
of first SGA; to 
sequential trials of 
FGAs and SGAs, 
switch to clozapine 
or another SGA or 
increase dose of 
SGA; to multiple 
previous trials 
including clozapine 
there was no expert 
consensus. 
 
For persistent 
negative symptoms, 
if the inadequate 
response was due: 
to FGA, switch to 
SGA; to SGA, 
switch to different 
SGA; to sequential 
trials of FGAs and 
SGAs, switch to 
clozapine or 
another SGA; to  
multiple previous 
trials including 
clozapine – no 
expert consensus 
Treatment non-
response to 
adequate trials of 
antipsychotic drugs 
from two different 
classes is an 
indication for a trial 
of clozapine 
If the patient is 
receiving an FGA 
and there are 
persistent 
symptoms or side-
effects, switch to an 
oral SGA.  
 
If the patient is 
receiving an FGA 
and was adherent 
to treatment, switch 
to an oral SGA. 
 
If treatment 
resistant 
schizophrenia is 
present, and at 
least two different 
antipsychotic drugs 
(at least one of the 
drugs should be a 
non-clozapine 
SGA), the offer the 
patient clozapine.  If 
resistance persists, 
the most effective 
prior drug should be 
reinstated and 
adjunctive therapy 
used e.g. lithium. 
 
If there is poor 
adherence, 
consider SGA-
depot/clozapine 
  
If the patient’s 
illness has not 
responded 
adequately to 
treatment despite 
the sequential use 
of adequate doses 
of at least two 
different 
antipsychotic drugs 
(at least one of the 
drugs should be a 
non-clozapine 
SGA), the offer the 
patient clozapine. 
 
For people with 
schizophrenia 
whose illness has 
not responded 
adequately to 
clozapine at an 
optimised dose, 
consider a second 
antipsychotic to 
augment treatment 
with clozapine.  An 
adequate trial of 
such an 
augmentation may 
need to be up to 8-
10 weeks.  Note: 
Choose a drug that 
does not compound 
the common side-
effects of clozapine 
If the patient is 
adhering to 
treatment and has 
an adequate 
plasma 
concentration of 
medication but is 
not responding to 
treatment, 
alternative 
treatment should be 
considered.   
 
If the patient is able 
to tolerate a higher 
dose of 
antipsychotic 
medication without 
significant side-
effects, raising the 
dose for a finite 
period, such as 2-4 
weeks, can be tried, 
although the 
incremental efficacy 
of higher doses has 
not been well 
established.  
 
If a dose adjustment 
does not result in an 
adequate response, 
a different 
antipsychotic 
medication should 
be considered 
Switching from one 
class of medication 
to another and 
using high doses of 
medication may be 
helpful.  Even within 
the FGAs, there is a 
range of medication 
including some 
agents with unique 
structures and 
mechanisms (e.g. 
pimozide).  
 
Most importantly, 
clozapine is a useful 
consideration.  
There is good 
evidence that 
clozapine can be 
effective in patients 
who have failed 
several previous 
trials of 
antipsychotics.   
 
Where severe 
symptoms are 
refractory to 
medication, the 
need for electro-
convulsive therapy 
should be 
considered.  
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Appendix B - Table 8 - Pharmacological management of extra-pyramidal side-effects 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Tardive dyskinesia If mild, switch to 
SGA.  
If severe, switch to 
clozapine or SGA 
   To manage tardive 
dyskinesia use 
SGA.  Can use 
clozapine 
 
 
Other 
extrapyramidal side-
effects 
 When used in 
recommended 
dosage range, risks 
of neurological side-
effects from SGAs 
are minimal.  A 
benzodiazepine or 
beta-blocker may 
be prescribed for 
akathisia if dosage 
reduction is 
insufficient.   
 
Anticholinergic 
medication is 
usually not 
recommended with 
the use of SGAs 
  If history of 
sensitivity to EPSE, 
use SGA except 
high doses of 
risperidone 
 
 
To treat EPSE other 
than tardive 
dyskinesia, use 
benztropine 
mesylate, 
trihexyphenidyl, 
amantadine, 
propranolol, 
lorazepam or 
diphenhydramine 
If patient is 
intolerant to a 
particular FGA, 
switch from high- to 
low-potency FGA or 
to SGA.  Reducing 
the dose of the 
antipsychotic and/or 
administering a 
short course of anti-
cholinergic 
medication 
prophylactically 
while the 
antipsychotic drug 
is being introduced 
 
Akathisia may be 
relieved by 
benzodiazepines, 
anti-cholinergic 
medications or 
beta-blockers  
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Appendix B - Table 9 - Depot formulation 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Depot formulation For patients who 
have had trouble 
taking oral 
medication reliably, 
who have poor 
insight/denial of 
illness, or who 
prefer depot 
 Depot should be 
reserved for two 
groups:  
- those who opt for 
it voluntarily, and 
- those who despite 
a series of 
comprehensive 
psychosocial 
interventions aimed 
at promoting 
adaptation and 
adherence 
repeatedly fail to 
adhere and relapse 
frequently 
 
Depot use in first 
episode patients: 
Depot may be an 
alternative to 
clozapine for poor 
adherence 
 
Depot medication in 
the management of 
acute relapse: Use 
the lowest possible 
dose and the 
maximum dosing 
interval.  Short-term 
benzodiazepines or 
oral neuroleptics 
supplementation 
may be required. 
Depot should be 
considered for 
people who would 
prefer this option 
after an acute 
episode or patients 
or to convert non-
adherence (either 
intentional or 
unintentional) to 
adherence is a 
clinical priority 
within the treatment 
plan 
 
At the start of 
treatment, give a 
dose at the lower 
end of the licensed 
range and titrate 
upward only within 
the dose range 
given in the British 
National Formulary 
or SPC 
Depot should be 
considered if the 
patient prefers or if 
repeated partial or 
full non-adherence 
to pharmacological 
treatment is present 
 
If depot is indicated 
the depot form of 
the same oral 
medication is the 
logical choice for 
initial treatment 
during the acute 
phase.  The 
transition from oral 
to long-acting 
injection form can 
begin during the 
acute phase; 
however, the long-
acting injection 
agents are not 
prescribed for acute 
psychotic episodes 
because these 
medications can 
take months to 
reach a stable 
steady-state and 
are eliminated very 
slowly 
 
Also see under 
polypharmacy 
Depot is a useful 
option in the non-
compliant patient 
with schizophrenia  
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Appendix B - Table 10 - Polypharmacy 
 
Recommendation ECGs 
(1999) 
CCPGs 
(2005) 
ANZGs 
(2005) 
NICEGs 
(2009) 
APAGs 
(2004) 
RSAGs 
(2005) 
Polypharmacy  Persistent positive 
symptoms: 
Use clozapine 
alone, then 
clozapine 
augmentation (e.g. 
lithium, 
anticonvulsants, 
antidepressants, 
benzodiazepines, 
ECT. 
 
Thereafter use 
combination 
strategies: these 
have been 
proposed 
essentially on the 
basis of case 
reports. 
Polypharmacy of 
any kind such as 
combination of an 
antipsychotic agent, 
a mood stabilizer 
and a 
benzodiazepine or 
an antidepressant, 
may be justified by 
comorbid symptom 
dimensions, which 
are extremely 
common in 
psychotic disorders.  
 
Antipsychotic 
polypharmacy: 
should not be used 
except during 
transitional periods 
when switching is in 
progress. There is 
little evidence that 
combining 
antipsychotic 
medications is 
useful; conversely 
this increases the 
side-effect burden 
Do not initiate 
regular combined 
antipsychotic 
medication except 
for short periods, 
e.g. when changing 
medication 
There may be 
circumstances with 
it is useful to 
prescribe a depot 
during acute 
treatment, e.g. if a 
patient experiences 
an exacerbation of 
psychotic symptoms 
while receiving 
depot it may be 
useful to continue 
the depot while 
temporarily 
supplementing it 
with oral medication 
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Appendix C 
Data collection form for the anonymous collection of 
prescription details – psychotropic drugs only 
 
 
Subject number (1 to 100)  
Duration of hospital stay  
 
Prescription on admission 
Drug No. Drug class Drug name Route Dosage Routine/PRN 
1      
2      
3      
4      
5      
6      
 
Prescription at 14 days after admission 
Drug No. Drug class Drug name Route Dosage Routine/PRN 
1      
2      
3      
4      
5      
6      
 
Prescription on discharge 
Drug No. Drug class Drug name Route Dosage Routine/PRN 
1      
2      
3      
4      
5      
6      
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Appendix D 
 
Formulary of relevant drugs available during the study 
 
Antipsychotic drugs 
amisulpride, chlorpromazine, clothiapine, clozapine, flupentixol, haloperidol, 
olanzapine, pimozide, risperidone (oral and depot forms), sulpiride, ziprasidone and 
zuclopenthixol. 
 
Anticholinergic drugs 
biperiden and orphenadrine 
 
Anxiolytic/Sedative-hypnotic drugs 
clonazepam, lorazepam, diazepam, oxazepam and zopiclone 
 
Mood stabilizers/Anticonvulsant drugs 
lithium carbonate, carbamazepine, lamotrigine, phenytoin, sodium valproate and 
valproic acid 
 
Antidepressant drugs 
amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, imipramine, 
mianserin, moclobemide, paroxetine, sertraline, tranylcypromine, trazodone and 
venlafaxine 
 
